US20190276432A1 - Covalent inhibitors of pad4 - Google Patents
Covalent inhibitors of pad4 Download PDFInfo
- Publication number
- US20190276432A1 US20190276432A1 US16/319,006 US201716319006A US2019276432A1 US 20190276432 A1 US20190276432 A1 US 20190276432A1 US 201716319006 A US201716319006 A US 201716319006A US 2019276432 A1 US2019276432 A1 US 2019276432A1
- Authority
- US
- United States
- Prior art keywords
- disease
- methyl
- cyclopropylmethyl
- pyrrolo
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 146
- 150000001875 compounds Chemical class 0.000 claims abstract description 144
- 239000000203 mixture Substances 0.000 claims abstract description 96
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 claims abstract description 71
- 101150094373 Padi4 gene Proteins 0.000 claims abstract description 71
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 claims abstract description 71
- -1 2-cyclopropyl Chemical group 0.000 claims description 87
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 23
- 125000001931 aliphatic group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 206010025135 lupus erythematosus Diseases 0.000 claims description 22
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 22
- 201000004681 Psoriasis Diseases 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 230000001404 mediated effect Effects 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 15
- 206010047115 Vasculitis Diseases 0.000 claims description 14
- 208000006673 asthma Diseases 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 11
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000011321 prophylaxis Methods 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- 239000003981 vehicle Substances 0.000 claims description 9
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 208000004852 Lung Injury Diseases 0.000 claims description 6
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 6
- 208000024780 Urticaria Diseases 0.000 claims description 6
- 231100000515 lung injury Toxicity 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 201000003274 CINCA syndrome Diseases 0.000 claims description 4
- 206010011878 Deafness Diseases 0.000 claims description 4
- 206010072224 Deficiency of the interleukin-1 receptor antagonist Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 208000037487 Endotoxemia Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 206010061481 Renal injury Diseases 0.000 claims description 4
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 4
- 239000013566 allergen Substances 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 206010002022 amyloidosis Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 208000016354 hearing loss disease Diseases 0.000 claims description 4
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 4
- 239000002085 irritant Substances 0.000 claims description 4
- 231100000021 irritant Toxicity 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 208000037806 kidney injury Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims description 4
- 230000002568 urticarial effect Effects 0.000 claims description 4
- 206010003011 Appendicitis Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 claims description 2
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 claims description 2
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 208000028185 Angioedema Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 206010002965 Aplasia pure red cell Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 206010003402 Arthropod sting Diseases 0.000 claims description 2
- 201000002909 Aspergillosis Diseases 0.000 claims description 2
- 208000036641 Aspergillus infections Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000027496 Behcet disease Diseases 0.000 claims description 2
- 206010004485 Berylliosis Diseases 0.000 claims description 2
- 208000009766 Blau syndrome Diseases 0.000 claims description 2
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000023355 Chronic beryllium disease Diseases 0.000 claims description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010058314 Dysplasia Diseases 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 201000011275 Epicondylitis Diseases 0.000 claims description 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 2
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000000203 Hyaline Membrane Disease Diseases 0.000 claims description 2
- 206010020575 Hyperammonaemia Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 claims description 2
- 206010021074 Hypoplastic anaemia Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000007031 Incontinentia pigmenti Diseases 0.000 claims description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 2
- 201000008450 Intracranial aneurysm Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 206010023439 Kidney transplant rejection Diseases 0.000 claims description 2
- 201000009324 Loeffler syndrome Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010072219 Mevalonic aciduria Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 206010051606 Necrotising colitis Diseases 0.000 claims description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- 206010070594 PFAPA syndrome Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 241001442654 Percnon planissimum Species 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010035742 Pneumonitis Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 206010036105 Polyneuropathy Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010039792 Seborrhoea Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 2
- 208000013200 Stress disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 208000004760 Tenosynovitis Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 241000159243 Toxicodendron radicans Species 0.000 claims description 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 230000001925 catabolic effect Effects 0.000 claims description 2
- 239000002561 chemical irritant Substances 0.000 claims description 2
- 201000004709 chorioretinitis Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 201000007717 corneal ulcer Diseases 0.000 claims description 2
- 231100000895 deafness Toxicity 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 claims description 2
- 208000026144 diffuse midline glioma, H3 K27M-mutant Diseases 0.000 claims description 2
- 208000030941 fetal growth restriction Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 208000024386 fungal infectious disease Diseases 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 230000001096 hypoplastic effect Effects 0.000 claims description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000004614 iritis Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000003265 lymphadenitis Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 2
- 230000002981 neuropathic effect Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- GTUJJVSZIHQLHA-XPWFQUROSA-N pApA Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 GTUJJVSZIHQLHA-XPWFQUROSA-N 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 230000007824 polyneuropathy Effects 0.000 claims description 2
- 230000010346 psychosocial stress Effects 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- DTXLBRAVKYTGFE-UHFFFAOYSA-J tetrasodium;2-(1,2-dicarboxylatoethylamino)-3-hydroxybutanedioate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)C(O)C(C([O-])=O)NC(C([O-])=O)CC([O-])=O DTXLBRAVKYTGFE-UHFFFAOYSA-J 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 208000016261 weight loss Diseases 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 89
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 75
- 239000000243 solution Substances 0.000 description 75
- 230000014759 maintenance of location Effects 0.000 description 71
- 235000002639 sodium chloride Nutrition 0.000 description 69
- 238000006243 chemical reaction Methods 0.000 description 62
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- 0 [1*]N1C(C2=CC3=C(C=CC=C3)N2[2*])=NC2=CC(C(C)=O)=CC([3*])=C21 Chemical compound [1*]N1C(C2=CC3=C(C=CC=C3)N2[2*])=NC2=CC(C(C)=O)=CC([3*])=C21 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 239000007787 solid Substances 0.000 description 46
- 235000019439 ethyl acetate Nutrition 0.000 description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 40
- 238000011282 treatment Methods 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 34
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 31
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- 229920006395 saturated elastomer Polymers 0.000 description 28
- 239000002904 solvent Substances 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 239000000843 powder Substances 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- 229910052938 sodium sulfate Inorganic materials 0.000 description 21
- 235000011152 sodium sulphate Nutrition 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 238000002953 preparative HPLC Methods 0.000 description 17
- 239000007821 HATU Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000003818 flash chromatography Methods 0.000 description 15
- UHXWDTIHVOAUPV-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carboxylic acid Chemical compound N=1C2=CC(C(O)=O)=CC=C2N(C)C=1C1=CC2=CC=CN=C2N1CC1CC1 UHXWDTIHVOAUPV-UHFFFAOYSA-N 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 235000019253 formic acid Nutrition 0.000 description 14
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 13
- 230000002378 acidificating effect Effects 0.000 description 13
- 239000003607 modifier Substances 0.000 description 13
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 230000002779 inactivation Effects 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000013058 crude material Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
- UUHNQHFOIVLAQX-BJILWQEISA-N (e)-4-(dimethylamino)but-2-enoic acid;hydrochloride Chemical compound Cl.CN(C)C\C=C\C(O)=O UUHNQHFOIVLAQX-BJILWQEISA-N 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000006329 citrullination Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- BQNAHEIXEFRGPB-UKTDVOJESA-N N-[(1S,4R,6S,7R)-7-amino-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-6-yl]-N-methylprop-2-enamide Chemical compound COc1cc(cc2nc(-c3cc4cccnc4n3CC3CC3)n(C)c12)C(=O)N1C[C@H]2C[C@@H]([C@@H]1[C@@H]2N)N(C)C(=O)C=C BQNAHEIXEFRGPB-UKTDVOJESA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000004749 rapidFire mass spectrometry Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 5
- BQNAHEIXEFRGPB-LEWOSNPHSA-N N-[(1S,4R,6R,7R)-7-amino-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-6-yl]-N-methylprop-2-enamide Chemical compound COc1cc(cc2nc(-c3cc4cccnc4n3CC3CC3)n(C)c12)C(=O)N1C[C@H]2C[C@H]([C@@H]1[C@@H]2N)N(C)C(=O)C=C BQNAHEIXEFRGPB-LEWOSNPHSA-N 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- DITCHUILFSNGME-UHFFFAOYSA-N methyl 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carboxylate Chemical compound COC(=O)c1ccc2n(C)c(nc2c1)-c1cc2cccnc2n1CC1CC1 DITCHUILFSNGME-UHFFFAOYSA-N 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ZXYBAHWXUGHXJH-MBHFTIIHSA-N tert-butyl N-[(1S,4R,6S,7R)-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-6-hydroxy-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2[C@H](C[C@H](C1)[C@H]2NC(OC(C)(C)C)=O)O)OC ZXYBAHWXUGHXJH-MBHFTIIHSA-N 0.000 description 5
- UAFUKXALTWNING-CCWPHWCFSA-N (E)-N-[(3R)-1-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]piperidin-3-yl]-4-(dimethylamino)but-2-enamide Chemical compound CN(C)C\C=C\C(=O)N[C@@H]1CCCN(C1)C(=O)C1=CC=C2N(C)C(=NC2=C1)C1=CC2=C(N=CC=C2)N1CC1CC1 UAFUKXALTWNING-CCWPHWCFSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- ZLBVSEGRTNQHQH-BJHKHANUSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,4R)-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyrrolidin-3-yl]-1-methylbenzimidazole-5-carboxamide Chemical compound CN(C)C\C=C\C(=O)N[C@@H]1CNC[C@H]1NC(=O)C1=CC=C2N(C)C(=NC2=C1)C1=CC2=C(N=CC=C2)N1CC1CC1 ZLBVSEGRTNQHQH-BJHKHANUSA-N 0.000 description 4
- ZLBVSEGRTNQHQH-UUMVYCCLSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-N-[(3S,4S)-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyrrolidin-3-yl]-1-methylbenzimidazole-5-carboxamide Chemical compound CN(C)C\C=C\C(=O)N[C@H]1CNC[C@@H]1NC(=O)C1=CC=C2N(C)C(=NC2=C1)C1=CC2=C(N=CC=C2)N1CC1CC1 ZLBVSEGRTNQHQH-UUMVYCCLSA-N 0.000 description 4
- CFELFOZOBIBTFL-FNORWQNLSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-N-[2-[[(E)-4-(dimethylamino)but-2-enoyl]amino]ethyl]-N-[2-(1H-imidazol-5-yl)ethyl]-1-methylbenzimidazole-5-carboxamide Chemical compound CN(C)C\C=C\C(=O)NCCN(CCC1=CN=CN1)C(=O)C1=CC=C2N(C)C(=NC2=C1)C1=CC2=C(N=CC=C2)N1CC1CC1 CFELFOZOBIBTFL-FNORWQNLSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- ZLBVSEGRTNQHQH-OIVIKFHHSA-N CN(C)C/C=C/C(=O)N[C@H]1CNCC1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C Chemical compound CN(C)C/C=C/C(=O)N[C@H]1CNCC1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C ZLBVSEGRTNQHQH-OIVIKFHHSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- ZXYSZYCQSXFBRN-OAQYLSRUSA-N N-[(3R)-1-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]piperidin-3-yl]prop-2-enamide Chemical compound CN1C2=CC=C(C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1)C(=O)N1CCC[C@H](C1)NC(=O)C=C ZXYSZYCQSXFBRN-OAQYLSRUSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- IDQBXRZJANNCFY-FSRHSHDFSA-N [(3r)-3-aminopiperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazol-5-yl]methanone;hydrochloride Chemical compound Cl.C=1C=C2N(C)C(C=3N(C4=NC=CC=C4C=3)CC3CC3)=NC2=CC=1C(=O)N1CCC[C@@H](N)C1 IDQBXRZJANNCFY-FSRHSHDFSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- UTXADZIKPXHWRX-UHFFFAOYSA-N dibenzyl 3-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]-3,6,7-triazabicyclo[3.2.1]octane-6,7-dicarboxylate Chemical compound Cn1c(nc2cc(ccc12)C(=O)N1CC2CC(C1)N(N2C(=O)OCc1ccccc1)C(=O)OCc1ccccc1)-c1cc2cccnc2n1CC1CC1 UTXADZIKPXHWRX-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000002552 multiple reaction monitoring Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102000001235 protein arginine deiminase Human genes 0.000 description 4
- 108060006632 protein arginine deiminase Proteins 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- HACUSTAWJYZZMM-BMQFZULRSA-N tert-butyl N-[(1S,4R,6S,7R)-6-hydroxy-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound C[C@H](N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2NC(=O)OC(C)(C)C)c1ccccc1 HACUSTAWJYZZMM-BMQFZULRSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- JQUQFKKTNVHCEV-JWZAGAIZSA-N (1R,4R,6S,7R)-7-bromo-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-6-ol Chemical compound Br[C@H]1[C@@H]2N(C[C@H]1C[C@@H]2O)[C@@H](C)C1=CC=CC=C1 JQUQFKKTNVHCEV-JWZAGAIZSA-N 0.000 description 3
- XGXSQSNIYVCGBD-UHFFFAOYSA-N 1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C(=O)O XGXSQSNIYVCGBD-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 101100123053 Arabidopsis thaliana GSH1 gene Proteins 0.000 description 3
- 101100298888 Arabidopsis thaliana PAD2 gene Proteins 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZKHVYQOALNTMJQ-UHFFFAOYSA-N N-(2-aminoethyl)-2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-1-methylbenzimidazole-5-carboxamide dihydrochloride Chemical compound Cl.Cl.Cn1c(nc2cc(ccc12)C(=O)N(CCN)CCc1cnc[nH]1)-c1cc2cccnc2n1CC1CC1 ZKHVYQOALNTMJQ-UHFFFAOYSA-N 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- KABBBXJFTRLKCT-BZNPZCIMSA-N O[C@H]1C[C@@H]2CN[C@H]1[C@@H]2NC(OC(C)(C)C)=O Chemical compound O[C@H]1C[C@@H]2CN[C@H]1[C@@H]2NC(OC(C)(C)C)=O KABBBXJFTRLKCT-BZNPZCIMSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 101150092599 Padi2 gene Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102100035735 Protein-arginine deiminase type-2 Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- SYYIWIMFBSKKFG-LYRKDJCHSA-N [(1S,4R,6S,7R)-7-amino-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-6-yl] prop-2-enoate Chemical compound C(C=C)(=O)O[C@H]1C[C@@H]2CN([C@H]1[C@@H]2N)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC SYYIWIMFBSKKFG-LYRKDJCHSA-N 0.000 description 3
- LGMQWHDIEKFXIE-XMSQKQJNSA-N [(3R,4R)-3-amino-4-hydroxypiperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound Cn1c(nc2cc(ccc12)C(=O)N1CC[C@@H](O)[C@H](N)C1)-c1cc2cccnc2n1CC1CC1 LGMQWHDIEKFXIE-XMSQKQJNSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- UOQRESVEXATCGD-UHFFFAOYSA-N methyl 3-amino-4-(methylamino)benzoate Chemical compound CNC1=CC=C(C(=O)OC)C=C1N UOQRESVEXATCGD-UHFFFAOYSA-N 0.000 description 3
- HIZRUIRMVQHKMB-UHFFFAOYSA-N methyl 3-amino-5-methoxy-4-(methylamino)benzoate Chemical compound NC=1C=C(C(=O)OC)C=C(C=1NC)OC HIZRUIRMVQHKMB-UHFFFAOYSA-N 0.000 description 3
- YIRXEGUDDPQTBF-UHFFFAOYSA-N methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate Chemical compound CNC1=C(OC)C=C(C(=O)OC)C=C1[N+]([O-])=O YIRXEGUDDPQTBF-UHFFFAOYSA-N 0.000 description 3
- RUJMPEWZLDVEAV-UHFFFAOYSA-N methyl 4-(methylamino)-3-nitrobenzoate Chemical compound CNC1=CC=C(C(=O)OC)C=C1[N+]([O-])=O RUJMPEWZLDVEAV-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- KEJPEOOLVRKRBG-YBMVJTLGSA-N tert-butyl (3R,4R)-3-[[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]amino]-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyrrolidine-1-carboxylate Chemical compound CN(C)C\C=C\C(=O)N[C@@H]1CN(C[C@H]1NC(=O)C1=CC=C2N(C)C(=NC2=C1)C1=CC2=C(N=CC=C2)N1CC1CC1)C(=O)OC(C)(C)C KEJPEOOLVRKRBG-YBMVJTLGSA-N 0.000 description 3
- XBUPXRAGBWOTSV-ZAUDBLIQSA-N tert-butyl N-[(1R,4R,6S,7R)-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-6-(methylamino)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2[C@H](C[C@H](C1)[C@H]2NC(OC(C)(C)C)=O)NC)OC XBUPXRAGBWOTSV-ZAUDBLIQSA-N 0.000 description 3
- JMFNCZMGGNIHSU-HHMXAWFKSA-N tert-butyl N-[(1R,4R,6S,7R)-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-6-(prop-2-enoylamino)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2[C@H](C[C@H](C1)[C@H]2NC(OC(C)(C)C)=O)NC(C=C)=O)OC JMFNCZMGGNIHSU-HHMXAWFKSA-N 0.000 description 3
- KURHPXSEPWINNH-WSAILGMDSA-N tert-butyl N-[(1R,4R,6S,7R)-6-amino-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound N[C@H]1C[C@@H]2CN([C@H]1[C@@H]2NC(OC(C)(C)C)=O)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC KURHPXSEPWINNH-WSAILGMDSA-N 0.000 description 3
- IKKWDDAHTNXAJE-JOCHJYFZSA-N tert-butyl N-[(3R)-1-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]piperidin-3-yl]carbamate Chemical compound Cn1c(nc2cc(ccc12)C(=O)N1CCC[C@H](C1)NC(=O)OC(C)(C)C)-c1cc2cccnc2n1CC1CC1 IKKWDDAHTNXAJE-JOCHJYFZSA-N 0.000 description 3
- SNFHFRRRYBHTHF-UHFFFAOYSA-N tert-butyl N-[2-[2-(1H-imidazol-5-yl)ethylamino]ethyl]carbamate Chemical compound N1C=NC=C1CCNCCNC(OC(C)(C)C)=O SNFHFRRRYBHTHF-UHFFFAOYSA-N 0.000 description 3
- HPAUHEVRMABHRL-UHFFFAOYSA-N tert-butyl N-[2-[[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]-[2-(1H-imidazol-5-yl)ethyl]amino]ethyl]carbamate Chemical compound CN1C2=CC=C(C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1)C(=O)N(CCNC(=O)OC(C)(C)C)CCC1=CN=CN1 HPAUHEVRMABHRL-UHFFFAOYSA-N 0.000 description 3
- ACNRTYKOPZDRCO-UHFFFAOYSA-N tert-butyl n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=O ACNRTYKOPZDRCO-UHFFFAOYSA-N 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- HDTOBFPLBMQQIQ-LLWAUHAZSA-N (1S,4R,6S,7R)-7-amino-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-6-ol hydrobromide Chemical compound Br.N[C@H]1[C@@H]2N(C[C@H]1C[C@@H]2O)[C@@H](C)C2=CC=CC=C2 HDTOBFPLBMQQIQ-LLWAUHAZSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- UIZWTUZQYPXHKI-FCIKTHLFSA-N 2-[1-(cyclopropylmethyl)indol-2-yl]-N-[(3R,4R)-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyrrolidin-3-yl]-7-methoxy-1-methylbenzimidazole-5-carboxamide Chemical compound COC1=C2N(C)C(=NC2=CC(=C1)C(=O)N[C@@H]1CNC[C@H]1NC(=O)\C=C\CN(C)C)C1=CC2=CC=CC=C2N1CC1CC1 UIZWTUZQYPXHKI-FCIKTHLFSA-N 0.000 description 2
- FRQAJXLMICKCKE-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carboxylic acid Chemical compound CN1C=2C(OC)=CC(C(O)=O)=CC=2N=C1C1=CC2=CC=CN=C2N1CC1CC1 FRQAJXLMICKCKE-UHFFFAOYSA-N 0.000 description 2
- IDZIZDCEWZVPPD-GZOLSCHFSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-N-[2-[[(E)-4-(dimethylamino)but-2-enoyl]amino]ethyl]-N-[2-(1H-imidazol-5-yl)ethyl]-1-methylbenzimidazole-5-carboxamide formic acid Chemical compound OC=O.CN(C)C\C=C\C(=O)NCCN(CCc1cnc[nH]1)C(=O)c1ccc2n(C)c(nc2c1)-c1cc2cccnc2n1CC1CC1 IDZIZDCEWZVPPD-GZOLSCHFSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- SWYXRJCDKIILPI-DMNFFOHLSA-N C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C Chemical compound C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C SWYXRJCDKIILPI-DMNFFOHLSA-N 0.000 description 2
- VDXCWBRWVWVJDC-FQEVSTJZSA-N C=CC(=O)C[C@@H]1CCCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1 Chemical compound C=CC(=O)C[C@@H]1CCCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1 VDXCWBRWVWVJDC-FQEVSTJZSA-N 0.000 description 2
- WBWYEJVHBIDJSF-FPQZTECRSA-N C=CC(=O)N(C)[C@@H]1C[C@@H]2CN(C(C)C)[C@H]1[C@@H]2N Chemical compound C=CC(=O)N(C)[C@@H]1C[C@@H]2CN(C(C)C)[C@H]1[C@@H]2N WBWYEJVHBIDJSF-FPQZTECRSA-N 0.000 description 2
- UUGKYBRZWXZXMI-GWQXNCQPSA-N C=CC(=O)O[C@@H]1CNCC1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C Chemical compound C=CC(=O)O[C@@H]1CNCC1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C UUGKYBRZWXZXMI-GWQXNCQPSA-N 0.000 description 2
- IDORHGCTLSPGGW-XKZLPGLHSA-N CC(C)N(C)[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C Chemical compound CC(C)N(C)[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C IDORHGCTLSPGGW-XKZLPGLHSA-N 0.000 description 2
- NHYGHSNBXYJERM-CJHOVAGGSA-N CN(C)C/C=C/C(=O)C[C@@H]1CCCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1 Chemical compound CN(C)C/C=C/C(=O)C[C@@H]1CCCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1 NHYGHSNBXYJERM-CJHOVAGGSA-N 0.000 description 2
- ZZZVARFXMJPSSY-UUUJUNNJSA-N CN(C)C/C=C/C(=O)C[C@@H]1C[C@H](N)CN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1 Chemical compound CN(C)C/C=C/C(=O)C[C@@H]1C[C@H](N)CN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1 ZZZVARFXMJPSSY-UUUJUNNJSA-N 0.000 description 2
- BBMJMTZTCXUMHA-URPFSFBESA-N CN(C)C/C=C/C(=O)N[C@@H]1CCCC(NC(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1 Chemical compound CN(C)C/C=C/C(=O)N[C@@H]1CCCC(NC(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1 BBMJMTZTCXUMHA-URPFSFBESA-N 0.000 description 2
- HKCDEONSLDDVOM-YIGOKMEQSA-N CN(C)C/C=C/C(=O)N[C@H]1CCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C[C@H]1N Chemical compound CN(C)C/C=C/C(=O)N[C@H]1CCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C[C@H]1N HKCDEONSLDDVOM-YIGOKMEQSA-N 0.000 description 2
- IRETXNFZYUBNPH-ORFRXJRVSA-N CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@H]1CNC[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.Cl.Cl.Cl Chemical compound CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@H]1CNC[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.Cl.Cl.Cl IRETXNFZYUBNPH-ORFRXJRVSA-N 0.000 description 2
- QCVXKQUVOKEFPR-RQUUXDSOSA-N CN(C)C/C=C/C(=O)N[C@H]1CNCC1N(C)C(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C Chemical compound CN(C)C/C=C/C(=O)N[C@H]1CNCC1N(C)C(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C QCVXKQUVOKEFPR-RQUUXDSOSA-N 0.000 description 2
- UIZWTUZQYPXHKI-TXPXDWFISA-N COC1=C2C(=CC(C(=O)NC3CNC[C@@H]3NC(=O)/C=C/CN(C)C)=C1)N=C(C1=CC3=C(C=CC=C3)N1CC1CC1)N2C Chemical compound COC1=C2C(=CC(C(=O)NC3CNC[C@@H]3NC(=O)/C=C/CN(C)C)=C1)N=C(C1=CC3=C(C=CC=C3)N1CC1CC1)N2C UIZWTUZQYPXHKI-TXPXDWFISA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- ALTLRGQMSDELBI-DBXGMPFESA-N N-[(1S,4R,6S,7R)-7-amino-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-6-yl]prop-2-enamide Chemical compound N[C@H]1[C@@H]2N(C[C@H]1C[C@@H]2NC(C=C)=O)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC ALTLRGQMSDELBI-DBXGMPFESA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- UUGKYBRZWXZXMI-UHFFFAOYSA-N [4-[[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]amino]pyrrolidin-3-yl] prop-2-enoate Chemical compound C(C=C)(=O)OC1CNCC1NC(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C=C1 UUGKYBRZWXZXMI-UHFFFAOYSA-N 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- CBIVEMGUNRNUEB-UHFFFAOYSA-N ethyl 1h-pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1=CN=C2NC(C(=O)OCC)=CC2=C1 CBIVEMGUNRNUEB-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- QNYHMMOXMRPWTK-UHFFFAOYSA-N methyl 4-chloro-3-methoxy-5-nitrobenzoate Chemical compound COC(=O)C1=CC(OC)=C(Cl)C([N+]([O-])=O)=C1 QNYHMMOXMRPWTK-UHFFFAOYSA-N 0.000 description 2
- CNJJSTPBUHAEFH-UHFFFAOYSA-N methyl 4-fluoro-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 CNJJSTPBUHAEFH-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- GYEMZAKFJNKYDL-CMTYHFORSA-N tert-butyl N-[(1S,4R,7R)-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-6-oxo-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2C(C[C@H](C1)[C@H]2NC(OC(C)(C)C)=O)=O)OC GYEMZAKFJNKYDL-CMTYHFORSA-N 0.000 description 2
- ZJHYRZDEDYIZIY-ZRSBARSZSA-N tert-butyl N-[(1S,4R,7R)-6-[benzyl(methyl)amino]-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound COc1cc(cc2nc(-c3cc4cccnc4n3CC3CC3)n(C)c12)C(=O)N1C[C@H]2CC([C@@H]1[C@@H]2NC(=O)OC(C)(C)C)N(C)Cc1ccccc1 ZJHYRZDEDYIZIY-ZRSBARSZSA-N 0.000 description 2
- WUOQXNWMYLFAHT-MRVPVSSYSA-N tert-butyl n-[(3r)-piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCNC1 WUOQXNWMYLFAHT-MRVPVSSYSA-N 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- HDTOBFPLBMQQIQ-GVGVMABMSA-N (1R,4R,6S,7R)-7-amino-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-6-ol hydrobromide Chemical compound Br.C[C@H](N1C[C@H]2C[C@H](O)[C@H]1[C@@H]2N)c1ccccc1 HDTOBFPLBMQQIQ-GVGVMABMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- RSDWJGVBOMNVSX-AKSWOFCCSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,4R)-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyrrolidin-3-yl]-1-methylbenzimidazole-5-carboxamide trihydrochloride Chemical compound Cl.Cl.Cl.C1(CC1)CN1C(=CC=2C1=NC=CC2)C2=NC1=C(N2C)C=CC(=C1)C(=O)N[C@@H]1CNC[C@H]1NC(\C=C\CN(C)C)=O RSDWJGVBOMNVSX-AKSWOFCCSA-N 0.000 description 1
- DAZHSFFBGMSDST-BRAPSYSQSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,4R)-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyrrolidin-3-yl]-N,1-dimethylbenzimidazole-5-carboxamide hydrochloride Chemical compound Cl.CN(C)C\C=C\C(=O)N[C@@H]1CNC[C@H]1N(C)C(=O)c1ccc2n(C)c(nc2c1)-c1cc2cccnc2n1CC1CC1 DAZHSFFBGMSDST-BRAPSYSQSA-N 0.000 description 1
- NMAQRFHMSVHUBV-FTLTYCHASA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,5S)-5-[[(E)-4-(dimethylamino)but-2-enoyl]amino]piperidin-3-yl]-1-methylbenzimidazole-5-carboxamide dihydrochloride Chemical compound Cl.Cl.C1(CC1)CN1C(=CC=2C1=NC=CC2)C2=NC1=C(N2C)C=CC(=C1)C(=O)N[C@H]1CNC[C@H](C1)NC(\C=C\CN(C)C)=O NMAQRFHMSVHUBV-FTLTYCHASA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- JFKBWUZRMSXFBO-UHFFFAOYSA-N BrCC1CC1.CCOC(=O)C1=CC2=CC=CN=C2N1.O=C(O)C1=CC2=CC=CN=C2N1CC1CC1 Chemical compound BrCC1CC1.CCOC(=O)C1=CC2=CC=CN=C2N1.O=C(O)C1=CC2=CC=CN=C2N1CC1CC1 JFKBWUZRMSXFBO-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- NKPJZGONJFDHNL-LONKJHDWSA-N C.CC(C)(C)OC(=O)N1C[C@H](N)[C@H](O)C1.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound C.CC(C)(C)OC(=O)N1C[C@H](N)[C@H](O)C1.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 NKPJZGONJFDHNL-LONKJHDWSA-N 0.000 description 1
- HAGOPGVDDHZXCG-HYILVKPZSA-N C.CC(C)(C)OC(=O)N[C@H]1[C@@H]2NC[C@H]1C[C@@H]2O.C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2NC(=O)OC(C)(C)C Chemical compound C.CC(C)(C)OC(=O)N[C@H]1[C@@H]2NC[C@H]1C[C@@H]2O.C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2NC(=O)OC(C)(C)C HAGOPGVDDHZXCG-HYILVKPZSA-N 0.000 description 1
- GWWZGNQUIXGZCN-ITMAYHADSA-N C.CN(C)C/C=C/C(=O)N[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C Chemical compound C.CN(C)C/C=C/C(=O)N[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C GWWZGNQUIXGZCN-ITMAYHADSA-N 0.000 description 1
- JLTMTWRXPJWERW-DEWBZNFLSA-N C.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N=[N+]=[N-])C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 Chemical compound C.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N=[N+]=[N-])C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 JLTMTWRXPJWERW-DEWBZNFLSA-N 0.000 description 1
- GXUOYKOYBDAABJ-IWFVHJIASA-N C.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3OS(C)(=O)=O)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 Chemical compound C.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3OS(C)(=O)=O)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 GXUOYKOYBDAABJ-IWFVHJIASA-N 0.000 description 1
- GNZCYAXDOCINNM-FWVYYFMGSA-N C.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 Chemical compound C.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 GNZCYAXDOCINNM-FWVYYFMGSA-N 0.000 description 1
- SMEGGUVPKJVHAH-UHFFFAOYSA-N C.CNC1=CC=C(C(=O)OC)C=C1N.CNC1=CC=C(C(=O)OC)C=C1[N+](=O)[O-] Chemical compound C.CNC1=CC=C(C(=O)OC)C=C1N.CNC1=CC=C(C(=O)OC)C=C1[N+](=O)[O-] SMEGGUVPKJVHAH-UHFFFAOYSA-N 0.000 description 1
- PMYOYDPRILKMKB-SNAWJCMRSA-N C/C=C/C(=O)NC(C)C Chemical compound C/C=C/C(=O)NC(C)C PMYOYDPRILKMKB-SNAWJCMRSA-N 0.000 description 1
- VYJNCTIXOADJCD-NUNSBDKSSA-N C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(C)C Chemical compound C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(C)C VYJNCTIXOADJCD-NUNSBDKSSA-N 0.000 description 1
- CAHYBODMOPYDBM-KCCRFRAFSA-N C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(C)C.CC(C)N(C)[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C.CC(C)N1CC[C@H](NC(=O)/C=C/CN(C)C)[C@H](N)C1.CC(C)N[C@@H]1CNC[C@H]1NC(=O)/C=C/CN(C)C.CC(C)N[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C Chemical compound C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(C)C.CC(C)N(C)[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C.CC(C)N1CC[C@H](NC(=O)/C=C/CN(C)C)[C@H](N)C1.CC(C)N[C@@H]1CNC[C@H]1NC(=O)/C=C/CN(C)C.CC(C)N[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C CAHYBODMOPYDBM-KCCRFRAFSA-N 0.000 description 1
- YZUOBTAENGVNKF-VENHEBQDSA-N C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(C)C.CC(C)N(CCNC(=O)/C=C/CN(C)C)CCC1=CN=CN1.CC(C)N1C[C@@H](N)C[C@@H](CC(=O)/C=C/CN(C)C)C1.CC(C)N[C@@H]1CNC[C@H]1NC(=O)/C=C/CN(C)C.CC(C)N[C@H]1CCC[C@@H](NC(=O)/C=C/CN(C)C)C1.CC(C)N[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C Chemical compound C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(C)C.CC(C)N(CCNC(=O)/C=C/CN(C)C)CCC1=CN=CN1.CC(C)N1C[C@@H](N)C[C@@H](CC(=O)/C=C/CN(C)C)C1.CC(C)N[C@@H]1CNC[C@H]1NC(=O)/C=C/CN(C)C.CC(C)N[C@H]1CCC[C@@H](NC(=O)/C=C/CN(C)C)C1.CC(C)N[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C YZUOBTAENGVNKF-VENHEBQDSA-N 0.000 description 1
- CMXNFXBFNYHFAL-UHFFFAOYSA-N C=CC(=O)CC(C)C Chemical compound C=CC(=O)CC(C)C CMXNFXBFNYHFAL-UHFFFAOYSA-N 0.000 description 1
- YZIADIOSIBRDKB-RVBUDDGFSA-N C=CC(=O)C[C@@H]1CCCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.C=CC(=O)Cl.CN1C2=CC=C(C(=O)N3CCC[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.[I-13] Chemical compound C=CC(=O)C[C@@H]1CCCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.C=CC(=O)Cl.CN1C2=CC=C(C(=O)N3CCC[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.[I-13] YZIADIOSIBRDKB-RVBUDDGFSA-N 0.000 description 1
- ZNXABFPHTYYTPP-NSHDSACASA-N C=CC(=O)C[C@@H]1CCCN(C(C)C)C1 Chemical compound C=CC(=O)C[C@@H]1CCCN(C(C)C)C1 ZNXABFPHTYYTPP-NSHDSACASA-N 0.000 description 1
- VDDKPLDJVJGYGD-NNKQJDDTSA-N C=CC(=O)C[C@@H]1CCCN(C(C)C)C1.C=CC(=O)O[C@@H]1CNC[C@@H]1NC(C)C.CC(C)N(CCNC(=O)/C=C/CN(C)C)CCC1=CN=CN1.CC(C)N1CCC[C@@H](CC(=O)/C=C/CN(C)C)C1.CC(C)N1C[C@@H](N)C[C@@H](CC(=O)/C=C/CN(C)C)C1.CC(C)N[C@H]1CCCC(NC(=O)/C=C/CN(C)C)C1 Chemical compound C=CC(=O)C[C@@H]1CCCN(C(C)C)C1.C=CC(=O)O[C@@H]1CNC[C@@H]1NC(C)C.CC(C)N(CCNC(=O)/C=C/CN(C)C)CCC1=CN=CN1.CC(C)N1CCC[C@@H](CC(=O)/C=C/CN(C)C)C1.CC(C)N1C[C@@H](N)C[C@@H](CC(=O)/C=C/CN(C)C)C1.CC(C)N[C@H]1CCCC(NC(=O)/C=C/CN(C)C)C1 VDDKPLDJVJGYGD-NNKQJDDTSA-N 0.000 description 1
- AWOMZRIQBABIKL-CCZKHLFDSA-N C=CC(=O)C[C@@H]1CCCN(C(C)C)C1.C=CC(=O)O[C@@H]1CNC[C@@H]1NC(C)C.CC(C)N1CCC[C@@H](CC(=O)/C=C/CN(C)C)C1 Chemical compound C=CC(=O)C[C@@H]1CCCN(C(C)C)C1.C=CC(=O)O[C@@H]1CNC[C@@H]1NC(C)C.CC(C)N1CCC[C@@H](CC(=O)/C=C/CN(C)C)C1 AWOMZRIQBABIKL-CCZKHLFDSA-N 0.000 description 1
- MBCDAYPWHVFUJI-JNEKXYPSSA-N C=CC(=O)C[C@H]1C[C@@H]2CN(C(=O)C3=CC4=C(C(OC)=C3)N(C)C(C3=CC5=CC=CN=C5N3CC3CC3)=N4)[C@H]1[C@@H]2N Chemical compound C=CC(=O)C[C@H]1C[C@@H]2CN(C(=O)C3=CC4=C(C(OC)=C3)N(C)C(C3=CC5=CC=CN=C5N3CC3CC3)=N4)[C@H]1[C@@H]2N MBCDAYPWHVFUJI-JNEKXYPSSA-N 0.000 description 1
- QCRYISQPIZUDLQ-FPQZTECRSA-N C=CC(=O)C[C@H]1C[C@@H]2CN(C(C)C)[C@H]1[C@@H]2N Chemical compound C=CC(=O)C[C@H]1C[C@@H]2CN(C(C)C)[C@H]1[C@@H]2N QCRYISQPIZUDLQ-FPQZTECRSA-N 0.000 description 1
- WPAOQVNVKIUKSN-OTTAAUIHSA-N C=CC(=O)Cl.C=CC(=O)O[C@@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound C=CC(=O)Cl.C=CC(=O)O[C@@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 WPAOQVNVKIUKSN-OTTAAUIHSA-N 0.000 description 1
- COYVWKMZTCAFHO-UHFFFAOYSA-N C=CC(=O)N(C)C(C)C Chemical compound C=CC(=O)N(C)C(C)C COYVWKMZTCAFHO-UHFFFAOYSA-N 0.000 description 1
- KRQREBKBWJPKEI-WIJPVVCBSA-N C=CC(=O)N(C)[C@@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2N.C=CC(=O)N(C)[C@@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.C=CC(=O)N(C)[C@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2N.C=CC(=O)N(C)[C@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.[I-16].[I-17] Chemical compound C=CC(=O)N(C)[C@@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2N.C=CC(=O)N(C)[C@@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.C=CC(=O)N(C)[C@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2N.C=CC(=O)N(C)[C@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.[I-16].[I-17] KRQREBKBWJPKEI-WIJPVVCBSA-N 0.000 description 1
- WBWYEJVHBIDJSF-LYIQGSDWSA-N C=CC(=O)N(C)[C@H]1C[C@@H]2CN(C(C)C)[C@H]1[C@@H]2N Chemical compound C=CC(=O)N(C)[C@H]1C[C@@H]2CN(C(C)C)[C@H]1[C@@H]2N WBWYEJVHBIDJSF-LYIQGSDWSA-N 0.000 description 1
- LYBIZMNPXTXVMV-UHFFFAOYSA-N C=CC(=O)OC(C)C Chemical compound C=CC(=O)OC(C)C LYBIZMNPXTXVMV-UHFFFAOYSA-N 0.000 description 1
- ZJXULZUVUKJNGU-DAHWIMEESA-N C=CC(=O)O[C@@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.C=CC(=O)O[C@@H]1CNC[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.Cl.Cl Chemical compound C=CC(=O)O[C@@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.C=CC(=O)O[C@@H]1CNC[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.Cl.Cl ZJXULZUVUKJNGU-DAHWIMEESA-N 0.000 description 1
- JSPMFWZZTRMMST-DTWKUNHWSA-N C=CC(=O)O[C@@H]1CNC[C@@H]1NC(C)C Chemical compound C=CC(=O)O[C@@H]1CNC[C@@H]1NC(C)C JSPMFWZZTRMMST-DTWKUNHWSA-N 0.000 description 1
- YOWFHULVINTMSV-UUXAENAASA-N C=CC(=O)O[C@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C Chemical compound C=CC(=O)O[C@H]1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C YOWFHULVINTMSV-UUXAENAASA-N 0.000 description 1
- CCPZMXKIQTXGMP-RBLKWDMZSA-N C=CC(=O)O[C@H]1C[C@@H]2CN(C(C)C)[C@H]1[C@@H]2N Chemical compound C=CC(=O)O[C@H]1C[C@@H]2CN(C(C)C)[C@H]1[C@@H]2N CCPZMXKIQTXGMP-RBLKWDMZSA-N 0.000 description 1
- CAYFSSFVKROZMD-JJVZPXIZSA-N CC(C)(C)CC(=O)N1CC[C@H](O)[C@@H](CC(=O)OCC2=CC=CC=C2)C1.CC(C)(C)OC(=O)N1CC[C@H](O)[C@@H](N)C1.O=C(Cl)OCC1=CC=CC=C1 Chemical compound CC(C)(C)CC(=O)N1CC[C@H](O)[C@@H](CC(=O)OCC2=CC=CC=C2)C1.CC(C)(C)OC(=O)N1CC[C@H](O)[C@@H](N)C1.O=C(Cl)OCC1=CC=CC=C1 CAYFSSFVKROZMD-JJVZPXIZSA-N 0.000 description 1
- AUFOQVTXUIMYAI-XFWHMTLOSA-N CC(C)(C)CC(=O)N1CC[C@H](O)[C@@H](CC(=O)OCC2=CC=CC=C2)C1.Cl.O=C(C[C@H]1CNCC[C@@H]1O)OCC1=CC=CC=C1 Chemical compound CC(C)(C)CC(=O)N1CC[C@H](O)[C@@H](CC(=O)OCC2=CC=CC=C2)C1.Cl.O=C(C[C@H]1CNCC[C@@H]1O)OCC1=CC=CC=C1 AUFOQVTXUIMYAI-XFWHMTLOSA-N 0.000 description 1
- JHJYZBAICVSGMD-VYQMDELVSA-N CC(C)(C)OC(=O)C[C@@H]1CCCNC1.CN1C2=CC=C(C(=O)N3CCC[C@@H](CC(=O)CC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(C=CC=C2)N1CC1CC1 Chemical compound CC(C)(C)OC(=O)C[C@@H]1CCCNC1.CN1C2=CC=C(C(=O)N3CCC[C@@H](CC(=O)CC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(C=CC=C2)N1CC1CC1 JHJYZBAICVSGMD-VYQMDELVSA-N 0.000 description 1
- NRHFGEIAMPEJLA-AOYCBHGVSA-N CC(C)(C)OC(=O)N1C[C@@H](N)C[C@@H](N)C1.CN1C2=CC=C(C(=O)N[C@H]3C[C@@H](N)CN(C(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CC(C)(C)OC(=O)N1C[C@@H](N)C[C@@H](N)C1.CN1C2=CC=C(C(=O)N[C@H]3C[C@@H](N)CN(C(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 NRHFGEIAMPEJLA-AOYCBHGVSA-N 0.000 description 1
- ROJMGNAYIKMCGV-DJFDELDSSA-N CC(C)(C)OC(=O)N1C[C@H](N)[C@@H](N)C1.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N)C=C2N=C1/C1=C/C2=CC=CN=C2N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 Chemical compound CC(C)(C)OC(=O)N1C[C@H](N)[C@@H](N)C1.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N)C=C2N=C1/C1=C/C2=CC=CN=C2N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 ROJMGNAYIKMCGV-DJFDELDSSA-N 0.000 description 1
- BDHJVQDUKJZMOC-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCCCCC1=CN=CC1.CN1C2=CC=C(C(=O)N(CCNC(=O)OC(C)(C)C)CCC3=CN=CN3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CC(C)(C)OC(=O)NCCCCCC1=CN=CC1.CN1C2=CC=C(C(=O)N(CCNC(=O)OC(C)(C)C)CCC3=CN=CN3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 BDHJVQDUKJZMOC-UHFFFAOYSA-N 0.000 description 1
- WBZXTCYZCLAXPO-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCCCCC1=CN=CC1.Cl.Cl.NCCC1=CN=CC1.[H]C(=O)CNC(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)NCCCCCC1=CN=CC1.Cl.Cl.NCCC1=CN=CC1.[H]C(=O)CNC(=O)OC(C)(C)C WBZXTCYZCLAXPO-UHFFFAOYSA-N 0.000 description 1
- ZSUCGKQACFUWPI-LNBSJMRSSA-N CC(C)(C)OC(=O)N[C@H]1[C@@H]2NC[C@H]1C[C@@H]2O.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)O)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C Chemical compound CC(C)(C)OC(=O)N[C@H]1[C@@H]2NC[C@H]1C[C@@H]2O.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)O)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C ZSUCGKQACFUWPI-LNBSJMRSSA-N 0.000 description 1
- LFWIDHGEVYTDTK-NDJXNIJKSA-N CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2N.C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2NC(=O)OC(C)(C)C.[H]Br Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2N.C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2NC(=O)OC(C)(C)C.[H]Br LFWIDHGEVYTDTK-NDJXNIJKSA-N 0.000 description 1
- BCCAKCKBDJFXMZ-UHFFFAOYSA-N CC(C)CSC(C)CC(=O)NC(C)C Chemical compound CC(C)CSC(C)CC(=O)NC(C)C BCCAKCKBDJFXMZ-UHFFFAOYSA-N 0.000 description 1
- UNUDDOZHFCPQKT-UHFFFAOYSA-N CC(C)CSC(CC(=O)NC(C)C)CN(C)C Chemical compound CC(C)CSC(CC(=O)NC(C)C)CN(C)C UNUDDOZHFCPQKT-UHFFFAOYSA-N 0.000 description 1
- GSTKYDBERVYFHP-UHFFFAOYSA-N CC(C)CSCCC(=O)CC(C)C Chemical compound CC(C)CSCCC(=O)CC(C)C GSTKYDBERVYFHP-UHFFFAOYSA-N 0.000 description 1
- VFLJIANGEAMGNH-UHFFFAOYSA-N CC(C)CSCCC(=O)OC(C)C Chemical compound CC(C)CSCCC(=O)OC(C)C VFLJIANGEAMGNH-UHFFFAOYSA-N 0.000 description 1
- PNMGNRUXCPXDGW-AATRIKPKSA-N CC(C)N(CCNC(=O)/C=C/CN(C)C)CCC1=CN=CN1 Chemical compound CC(C)N(CCNC(=O)/C=C/CN(C)C)CCC1=CN=CN1 PNMGNRUXCPXDGW-AATRIKPKSA-N 0.000 description 1
- TVUIOTCDCXHSFB-UHFFFAOYSA-N CC(C)N(CCc1cnc[nH]1)CCNC(CCCN(C)C)=O Chemical compound CC(C)N(CCc1cnc[nH]1)CCNC(CCCN(C)C)=O TVUIOTCDCXHSFB-UHFFFAOYSA-N 0.000 description 1
- FPWZJGWJRVLXET-OWNNVSBGSA-N CC(C)N1CCC[C@@H](CC(=O)/C=C/CN(C)C)C1 Chemical compound CC(C)N1CCC[C@@H](CC(=O)/C=C/CN(C)C)C1 FPWZJGWJRVLXET-OWNNVSBGSA-N 0.000 description 1
- QWPFZBZOKITAQG-PBJSTTKNSA-N CC(C)N1CC[C@H](NC(=O)/C=C/CN(C)C)[C@H](N)C1 Chemical compound CC(C)N1CC[C@H](NC(=O)/C=C/CN(C)C)[C@H](N)C1 QWPFZBZOKITAQG-PBJSTTKNSA-N 0.000 description 1
- XJKHVHJYNWOVNT-BEVHLOIGSA-N CC(C)N1C[C@@H](N)C[C@@H](CC(=O)/C=C/CN(C)C)C1 Chemical compound CC(C)N1C[C@@H](N)C[C@@H](CC(=O)/C=C/CN(C)C)C1 XJKHVHJYNWOVNT-BEVHLOIGSA-N 0.000 description 1
- ZNCPXCWBGJGONJ-AATRIKPKSA-N CC(C)NC(=O)/C=C/CN(C)C Chemical compound CC(C)NC(=O)/C=C/CN(C)C ZNCPXCWBGJGONJ-AATRIKPKSA-N 0.000 description 1
- UWYYBFKDAVEGPT-IEVRTODYSA-N CC(C)N[C@@H]1CNC[C@H]1NC(=O)/C=C/CN(C)C Chemical compound CC(C)N[C@@H]1CNC[C@H]1NC(=O)/C=C/CN(C)C UWYYBFKDAVEGPT-IEVRTODYSA-N 0.000 description 1
- BZEHAPDWHQJGEO-HPPUWWEISA-N CC(C)N[C@H]1CCCC(NC(=O)/C=C/CN(C)C)C1 Chemical compound CC(C)N[C@H]1CCCC(NC(=O)/C=C/CN(C)C)C1 BZEHAPDWHQJGEO-HPPUWWEISA-N 0.000 description 1
- UWYYBFKDAVEGPT-WTIVYXKASA-N CC(C)N[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C Chemical compound CC(C)N[C@H]1CNC[C@@H]1NC(=O)/C=C/CN(C)C UWYYBFKDAVEGPT-WTIVYXKASA-N 0.000 description 1
- RKVXUPUJFHGJEF-GMCFVEKCSA-N CC/C=C/C(N[C@H](CNC1)[C@@H]1NCC)=O Chemical compound CC/C=C/C(N[C@H](CNC1)[C@@H]1NCC)=O RKVXUPUJFHGJEF-GMCFVEKCSA-N 0.000 description 1
- JQXNUQQECCTGRB-UHFFFAOYSA-N CCNC(CCSCC)=O Chemical compound CCNC(CCSCC)=O JQXNUQQECCTGRB-UHFFFAOYSA-N 0.000 description 1
- MNOFYIDOBNGSDP-GBODTJMESA-N CN(C)C/C=C/C(=O)C[C@@H]1CCCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N3CCC[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.Cl.[I-12] Chemical compound CN(C)C/C=C/C(=O)C[C@@H]1CCCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N3CCC[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.Cl.[I-12] MNOFYIDOBNGSDP-GBODTJMESA-N 0.000 description 1
- UJVWEWGQGZGDCQ-DXIIEZRQSA-N CN(C)C/C=C/C(=O)NCCN(CCC1=CN=CN1)C(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N(CCN)CCC3=CN=CN3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.Cl.Cl.O=CO Chemical compound CN(C)C/C=C/C(=O)NCCN(CCC1=CN=CN1)C(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N(CCN)CCC3=CN=CN3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.Cl.Cl.O=CO UJVWEWGQGZGDCQ-DXIIEZRQSA-N 0.000 description 1
- DELRUCQZYOOADD-KWNAGXOKSA-N CN(C)C/C=C/C(=O)N[C@@H]1CCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C[C@@H]1CC(=O)OC(C)(C)C.CN(C)C/C=C/C(=O)N[C@@H]1CCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C[C@@H]1N Chemical compound CN(C)C/C=C/C(=O)N[C@@H]1CCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C[C@@H]1CC(=O)OC(C)(C)C.CN(C)C/C=C/C(=O)N[C@@H]1CCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C[C@@H]1N DELRUCQZYOOADD-KWNAGXOKSA-N 0.000 description 1
- KGNVWSQAMPHVEV-PQWGMSJPSA-N CN(C)C/C=C/C(=O)N[C@@H]1CCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C[C@@H]1CC(=O)OC(C)(C)C.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N3CC[C@@H](N)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CN(C)C/C=C/C(=O)N[C@@H]1CCN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C[C@@H]1CC(=O)OC(C)(C)C.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N3CC[C@@H](N)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 KGNVWSQAMPHVEV-PQWGMSJPSA-N 0.000 description 1
- IRETXNFZYUBNPH-OVRYDYRRSA-N CN(C)C/C=C/C(=O)N[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H]1NC(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.Cl.Cl.Cl Chemical compound CN(C)C/C=C/C(=O)N[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H]1NC(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@@H]1CNC[C@H]1NC(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.Cl.Cl.Cl IRETXNFZYUBNPH-OVRYDYRRSA-N 0.000 description 1
- IRCUTXLEOZEHTH-JPGGZPEVSA-N CN(C)C/C=C/C(=O)N[C@@H]1C[C@H](NC(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)CN(C(=O)OC(C)(C)C)C1.CN(C)C/C=C/C(=O)N[C@H]1CCC[C@@H](NC(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.Cl Chemical compound CN(C)C/C=C/C(=O)N[C@@H]1C[C@H](NC(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)CN(C(=O)OC(C)(C)C)C1.CN(C)C/C=C/C(=O)N[C@H]1CCC[C@@H](NC(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.Cl IRCUTXLEOZEHTH-JPGGZPEVSA-N 0.000 description 1
- ZUBFBVJZXIRWAQ-JARJQWICSA-N CN(C)C/C=C/C(=O)N[C@@H]1C[C@H](NC(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)CN(C(=O)OC(C)(C)C)C1.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N[C@H]3C[C@@H](N)CN(C(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl Chemical compound CN(C)C/C=C/C(=O)N[C@@H]1C[C@H](NC(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)CN(C(=O)OC(C)(C)C)C1.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N[C@H]3C[C@@H](N)CN(C(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl ZUBFBVJZXIRWAQ-JARJQWICSA-N 0.000 description 1
- FXRDKAIKWUTWFD-QFJWJVHCSA-N CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1N(C)C(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@H]1CNC[C@@H]1N(C)C(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.Cl.Cl Chemical compound CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1N(C)C(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)N[C@H]1CNC[C@@H]1N(C)C(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.Cl.Cl FXRDKAIKWUTWFD-QFJWJVHCSA-N 0.000 description 1
- QVVHMQZQYJOGFS-XNHUZOLFSA-N CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1N(C)C(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.Cl Chemical compound CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1N(C)C(=O)C1=CC=C2C(=C1)N=C(/C1=C/C3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.Cl QVVHMQZQYJOGFS-XNHUZOLFSA-N 0.000 description 1
- VVMRBWVZQFYPCJ-PHVCBABZSA-N CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N)C=C2N=C1C1=CC2=CC=CN=C2N1CC1CC1.Cl Chemical compound CN(C)C/C=C/C(=O)N[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1NC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N)C=C2N=C1C1=CC2=CC=CN=C2N1CC1CC1.Cl VVMRBWVZQFYPCJ-PHVCBABZSA-N 0.000 description 1
- JDDPHPNBUKIOKH-ZXKVKBEPSA-N CN(C)C/C=C/C(=O)N[C@H]1C[C@@H](CC(=O)OC(C)(C)C)CN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.CN(C)C/C=C/C(=O)N[C@H]1C[C@@H](N)CN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.Cl Chemical compound CN(C)C/C=C/C(=O)N[C@H]1C[C@@H](CC(=O)OC(C)(C)C)CN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.CN(C)C/C=C/C(=O)N[C@H]1C[C@@H](N)CN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.Cl JDDPHPNBUKIOKH-ZXKVKBEPSA-N 0.000 description 1
- MWDJLNQVWYDRRE-LLIMHISPSA-N CN(C)C/C=C/C(=O)N[C@H]1C[C@@H](CC(=O)OC(C)(C)C)CN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N3C[C@@H](N)C[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CN(C)C/C=C/C(=O)N[C@H]1C[C@@H](CC(=O)OC(C)(C)C)CN(C(=O)C2=CC=C3C(=C2)N=C(C2=CC4=C(N=CC=C4)N2CC2CC2)N3C)C1.CN(C)C/C=C/C(=O)O.CN1C2=CC=C(C(=O)N3C[C@@H](N)C[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 MWDJLNQVWYDRRE-LLIMHISPSA-N 0.000 description 1
- OYDJJYOKAGHESP-UHFFFAOYSA-N CN.CNC1=C(OC)C=C(C(=O)OC)C=C1N.CNC1=C(OC)C=C(C(=O)OC)C=C1[N+](=O)[O-].COC(=O)C1=CC(OC)=C(Cl)C([N+](=O)[O-])=C1.Cl Chemical compound CN.CNC1=C(OC)C=C(C(=O)OC)C=C1N.CNC1=C(OC)C=C(C(=O)OC)C=C1[N+](=O)[O-].COC(=O)C1=CC(OC)=C(Cl)C([N+](=O)[O-])=C1.Cl OYDJJYOKAGHESP-UHFFFAOYSA-N 0.000 description 1
- XJANOBAUHUUQJO-UHFFFAOYSA-N CN.CNC1=CC=C(C(=O)OC)C=C1[N+](=O)[O-].COC(=O)C1=CC=C(F)C([N+](=O)[O-])=C1 Chemical compound CN.CNC1=CC=C(C(=O)OC)C=C1[N+](=O)[O-].COC(=O)C1=CC=C(F)C([N+](=O)[O-])=C1 XJANOBAUHUUQJO-UHFFFAOYSA-N 0.000 description 1
- MBJZVIHMTWYJNX-CCAJDOSESA-N CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N=[N+]=[N-])C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3OS(C)(=O)=O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.[N-]=[N+]=N[Na] Chemical compound CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]3N=[N+]=[N-])C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3OS(C)(=O)=O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.[N-]=[N+]=N[Na] MBJZVIHMTWYJNX-CCAJDOSESA-N 0.000 description 1
- AURILMCINYSEEP-JKSGSWSJSA-N CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 Chemical compound CN1C2=CC=C(C(=O)N(C)[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N[C@H]3CN(C(=O)OC(C)(C)C)C[C@H]3O[Si](C)(C)C(C)(C)C)C=C2N=C1/C1=C/C2=C(N=CC=C2)N1CC1CC1 AURILMCINYSEEP-JKSGSWSJSA-N 0.000 description 1
- ZNWVNRVVPQYVPW-UHFFFAOYSA-N CN1C2=CC=C(C(=O)N(CCN)CCC3=CN=CN3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N(CCNC(=O)OC(C)(C)C)CCC3=CN=CN3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.Cl.Cl Chemical compound CN1C2=CC=C(C(=O)N(CCN)CCC3=CN=CN3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N(CCNC(=O)OC(C)(C)C)CCC3=CN=CN3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.Cl.Cl ZNWVNRVVPQYVPW-UHFFFAOYSA-N 0.000 description 1
- UCSYNXUVAFGMBC-GRZLYNJPSA-N CN1C2=CC=C(C(=O)N3CC4CC(C3)N(C(=O)OCC3=CC=CC=C3)N4C(=O)OCC3=CC=CC=C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3C[C@@H](N)C[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CN1C2=CC=C(C(=O)N3CC4CC(C3)N(C(=O)OCC3=CC=CC=C3)N4C(=O)OCC3=CC=CC=C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3C[C@@H](N)C[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 UCSYNXUVAFGMBC-GRZLYNJPSA-N 0.000 description 1
- HTWPGGRWYHTAJC-UHFFFAOYSA-N CN1C2=CC=C(C(=O)N3CC4CC(C3)N(C(=O)OCC3=CC=CC=C3)N4C(=O)OCC3=CC=CC=C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.O=C(OCC1=CC=CC=C1)N1C2CNCC(C2)N1C(=O)OCC1=CC=CC=C1 Chemical compound CN1C2=CC=C(C(=O)N3CC4CC(C3)N(C(=O)OCC3=CC=CC=C3)N4C(=O)OCC3=CC=CC=C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.O=C(OCC1=CC=CC=C1)N1C2CNCC(C2)N1C(=O)OCC1=CC=CC=C1 HTWPGGRWYHTAJC-UHFFFAOYSA-N 0.000 description 1
- QVRREUHPOPHUFJ-BTVIOREBSA-N CN1C2=CC=C(C(=O)N3CCC[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CCC[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.Cl Chemical compound CN1C2=CC=C(C(=O)N3CCC[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CCC[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.Cl QVRREUHPOPHUFJ-BTVIOREBSA-N 0.000 description 1
- VKRJOJLJBYMJHZ-CGUNPHQTSA-N CN1C2=CC=C(C(=O)N3CC[C@@H](N)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@@H](N=[N+]=[N-])[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CN1C2=CC=C(C(=O)N3CC[C@@H](N)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@@H](N=[N+]=[N-])[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 VKRJOJLJBYMJHZ-CGUNPHQTSA-N 0.000 description 1
- PXIZFDIBKORHTE-YGTHGFOQSA-N CN1C2=CC=C(C(=O)N3CC[C@@H](N=[N+]=[N-])[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@H](OS(C)(=O)=O)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CN1C2=CC=C(C(=O)N3CC[C@@H](N=[N+]=[N-])[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@H](OS(C)(=O)=O)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 PXIZFDIBKORHTE-YGTHGFOQSA-N 0.000 description 1
- SFQKZRMEGIMAFT-VQQTZIHLSA-N CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 SFQKZRMEGIMAFT-VQQTZIHLSA-N 0.000 description 1
- JBSTUHKWZRUNDK-OHRJUJGJSA-N CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@H](OS(C)(=O)=O)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@H](OS(C)(=O)=O)[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 JBSTUHKWZRUNDK-OHRJUJGJSA-N 0.000 description 1
- FABDNHVEDFQENW-APICNRSSSA-N CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](CC(=O)OCC4=CC=CC=C4)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](CC(=O)OCC4=CC=CC=C4)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 FABDNHVEDFQENW-APICNRSSSA-N 0.000 description 1
- GCDPKDFRVZOYGY-IWLUQYCOSA-N CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](CC(=O)OCC4=CC=CC=C4)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.O=C(C[C@H]1CNCC[C@@H]1O)OCC1=CC=CC=C1 Chemical compound CN1C2=CC=C(C(=O)N3CC[C@H](O)[C@@H](CC(=O)OCC4=CC=CC=C4)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.Cl.O=C(C[C@H]1CNCC[C@@H]1O)OCC1=CC=CC=C1 GCDPKDFRVZOYGY-IWLUQYCOSA-N 0.000 description 1
- ISODQSXJBLAKSM-KAKSZVIXSA-N CN1C2=CC=C(C(=O)N3C[C@@H](N)C[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3C[C@@H](N)C[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 Chemical compound CN1C2=CC=C(C(=O)N3C[C@@H](N)C[C@@H](CC(=O)OC(C)(C)C)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.CN1C2=CC=C(C(=O)N3C[C@@H](N)C[C@@H](N)C3)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1 ISODQSXJBLAKSM-KAKSZVIXSA-N 0.000 description 1
- BOLKVCQPTURWLL-UHFFFAOYSA-N CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.COC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C Chemical compound CN1C2=CC=C(C(=O)O)C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1.COC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C BOLKVCQPTURWLL-UHFFFAOYSA-N 0.000 description 1
- WATVNAZANWHZBN-UHFFFAOYSA-N CNC1=CC=C(C(=O)OC)C=C1N.COC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.O=C(O)C1=CC2=CC=CN=C2N1CC1CC1 Chemical compound CNC1=CC=C(C(=O)OC)C=C1N.COC(=O)C1=CC=C2C(=C1)N=C(C1=CC3=C(N=CC=C3)N1CC1CC1)N2C.O=C(O)C1=CC2=CC=CN=C2N1CC1CC1 WATVNAZANWHZBN-UHFFFAOYSA-N 0.000 description 1
- CQPLPRKLHMSRJX-OHLCJWKPSA-N CNC1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.COC1=C2C(=CC(C(=O)N3C[C@H]4CC(N(C)C(C)=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C Chemical compound CNC1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.COC1=C2C(=CC(C(=O)N3C[C@H]4CC(N(C)C(C)=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C CQPLPRKLHMSRJX-OHLCJWKPSA-N 0.000 description 1
- PTIMERKSSLGEPN-HMVKANTNSA-N CNC1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.COC1=C2C(=CC(C(=O)N3C[C@H]4CC(N(C)CC5=CC=CC=C5)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C Chemical compound CNC1C[C@@H]2CN(C(=O)C3=CC(OC)=C4C(=C3)N=C(C3=CC5=CC=CN=C5N3CC3CC3)N4C)[C@H]1[C@@H]2NC(=O)OC(C)(C)C.COC1=C2C(=CC(C(=O)N3C[C@H]4CC(N(C)CC5=CC=CC=C5)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C PTIMERKSSLGEPN-HMVKANTNSA-N 0.000 description 1
- HJUVKCDIBUYWAI-ZVZSFFEFSA-N COC1=C2C(=CC(C(=O)N3C[C@H]4CC(=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4CC(N(C)CC5=CC=CC=C5)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C Chemical compound COC1=C2C(=CC(C(=O)N3C[C@H]4CC(=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4CC(N(C)CC5=CC=CC=C5)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C HJUVKCDIBUYWAI-ZVZSFFEFSA-N 0.000 description 1
- KRDOKPXBUTVBEH-KXKQXBSSSA-N COC1=C2C(=CC(C(=O)N3C[C@H]4CC(=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C Chemical compound COC1=C2C(=CC(C(=O)N3C[C@H]4CC(=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C KRDOKPXBUTVBEH-KXKQXBSSSA-N 0.000 description 1
- ZFSFMGLLMRBXJI-DDIZJCDOSA-N COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](CC(C)=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](N)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C Chemical compound COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](CC(C)=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](N)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C ZFSFMGLLMRBXJI-DDIZJCDOSA-N 0.000 description 1
- GJCCBOZWPMBHNB-ONEQWFSFSA-N COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](N)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](N5C(=O)C6=CC=CC=C6C5=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C Chemical compound COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](N)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](N5C(=O)C6=CC=CC=C6C5=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C GJCCBOZWPMBHNB-ONEQWFSFSA-N 0.000 description 1
- XRVVBNGDCBFNSY-RPMNKBJDSA-N COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](N5C(=O)C6=CC=CC=C6C5=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C Chemical compound COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](N5C(=O)C6=CC=CC=C6C5=O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C.COC1=C2C(=CC(C(=O)N3C[C@H]4C[C@H](O)[C@@H]3[C@@H]4NC(=O)OC(C)(C)C)=C1)N=C(C1=CC3=CC=CN=C3N1CC1CC1)N2C XRVVBNGDCBFNSY-RPMNKBJDSA-N 0.000 description 1
- AIMBGESASAJVPC-NSJNJNCDSA-N C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2Br.C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2N.N.[H]Br Chemical compound C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2Br.C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2N.N.[H]Br AIMBGESASAJVPC-NSJNJNCDSA-N 0.000 description 1
- JOFMJIAUBNIPKR-JGGUJOAQSA-N C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2Br.C[C@@H](C1=CC=CC=C1)[N+]12C[C@H]3C[C@@H]1C2C3Br.[Br-] Chemical compound C[C@@H](C1=CC=CC=C1)N1C[C@H]2C[C@H](O)[C@@H]1[C@@H]2Br.C[C@@H](C1=CC=CC=C1)[N+]12C[C@H]3C[C@@H]1C2C3Br.[Br-] JOFMJIAUBNIPKR-JGGUJOAQSA-N 0.000 description 1
- VQPPOXBPURDHRS-JWZAGAIZSA-N C[C@@H](c1ccccc1)N(C[C@H]1C[C@@H]2O)[C@H]2[C@@H]1N Chemical compound C[C@@H](c1ccccc1)N(C[C@H]1C[C@@H]2O)[C@H]2[C@@H]1N VQPPOXBPURDHRS-JWZAGAIZSA-N 0.000 description 1
- GJAZWXKNQIZRAB-KDURUIRLSA-N C[n]1c(-c([n]2CC3CC3)cc3c2nccc3)nc2cc(C(N(C[C@@H](C3)N)C[C@H]3N)=O)ccc12 Chemical compound C[n]1c(-c([n]2CC3CC3)cc3c2nccc3)nc2cc(C(N(C[C@@H](C3)N)C[C@H]3N)=O)ccc12 GJAZWXKNQIZRAB-KDURUIRLSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- BPWATVWOHQZVRP-NSHDSACASA-N Cl-Amidine Chemical compound ClCC(=N)NCCC[C@@H](C(=O)N)NC(=O)C1=CC=CC=C1 BPWATVWOHQZVRP-NSHDSACASA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100025721 Cytosolic carboxypeptidase 2 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101000932634 Homo sapiens Cytosolic carboxypeptidase 2 Proteins 0.000 description 1
- 101000735566 Homo sapiens Protein-arginine deiminase type-4 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101001033011 Mus musculus Granzyme C Proteins 0.000 description 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N NCCc1cnc[nH]1 Chemical compound NCCc1cnc[nH]1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229940122298 Peptidyl arginine deiminase IV inhibitor Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006217 arginine-methylation Effects 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PKTGTECRFNOEKN-MNMPKAIFSA-N benzyl N-[(3R,4R)-4-hydroxypiperidin-3-yl]carbamate hydrochloride Chemical compound Cl.O[C@@H]1CCNC[C@H]1NC(=O)OCc1ccccc1 PKTGTECRFNOEKN-MNMPKAIFSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108091006007 citrullinated proteins Proteins 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- FWPCZXLENBKKNA-UHFFFAOYSA-N dibenzyl 3,6,7-triazabicyclo[3.2.1]octane-6,7-dicarboxylate Chemical compound C12CNCC(N(N1C(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)C2 FWPCZXLENBKKNA-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 102000044110 human PADI4 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000007820 inflammatory cell apoptotic process Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DPDIOBBGKGZFDI-LOSJGSFVSA-N tert-butyl (3S,4R)-3-[[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]-methylamino]-4-hydroxypyrrolidine-1-carboxylate Chemical compound CN([C@H]1CN(C[C@H]1O)C(=O)OC(C)(C)C)C(=O)C1=CC=C2N(C)C(=NC2=C1)C1=CC2=C(N=CC=C2)N1CC1CC1 DPDIOBBGKGZFDI-LOSJGSFVSA-N 0.000 description 1
- KEJPEOOLVRKRBG-YURVUCAZSA-N tert-butyl (3S,4S)-3-[[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]amino]-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyrrolidine-1-carboxylate Chemical compound CN(C)C\C=C\C(=O)N[C@H]1CN(C[C@@H]1NC(=O)C1=CC=C2N(C)C(=NC2=C1)C1=CC2=C(N=CC=C2)N1CC1CC1)C(=O)OC(C)(C)C KEJPEOOLVRKRBG-YURVUCAZSA-N 0.000 description 1
- KPIFIDHWGDEHJD-UHFFFAOYSA-N tert-butyl 3-[[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carbonyl]amino]-4-hydroxypyrrolidine-1-carboxylate Chemical compound CN1C2=CC=C(C=C2N=C1C1=CC2=C(N=CC=C2)N1CC1CC1)C(=O)NC1CN(CC1O)C(=O)OC(C)(C)C KPIFIDHWGDEHJD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- PAD4 is a member of the peptidylarginine deiminase (PAD) family of enzymes capable of catalysing the citrullination of arginine into citrulline within peptide sequences. PAD4 is responsible for the deimination or citrullination of a variety of proteins in vitro and in vivo, with consequences of diverse functional responses in a variety of diseases (Jones J. E. et al, Curr. Opin. Drug Discov. Devel., 12(5), (2009), 616-627).
- PAD peptidylarginine deiminase
- exemplar diseases include rheumatoid arthritis, diseases with neutrophilic contributions to pathogenesis (for example vasculitis, systemic lupus erythematosus, ulcerative colitis) in addition to oncology indications.
- PAD4 inhibitors also have wider applicability as tools and therapeutics for human disease through epigenetic mechanisms.
- RA Rheumatoid Arthritis
- RA is an auto-immune disease affecting approximately 1% of the population (Wegner N. et al, Immunol. Rev., 233(1) (2010), 34-54). It is characterised by inflammation of articular joints leading to debilitating destruction of bone and cartilage.
- a weak genetic association between PAD4 polymorphisms and susceptibility to RA has been suggested, albeit inconsistently, in a number of population studies (Kochi Y. et al, Ann. Rheum. Dis., 70, (2011), 512-515).
- PAD4 (along with family member PAD2) has been detected in synovial tissue where it is responsible for the deimination of a variety of joint proteins. This process is presumed to lead to a break of tolerance to, and initiation of immune responses to, citrullinated substrates such as fibrinogen, vimentin and collagen in RA joints.
- ACPA anti-citrullinated protein antibodies
- PAD4 contribute to disease pathogenesis and may also be used as a diagnostic test for RA (e.g. the commercially available CCP2 or cyclic citrullinated protein 2 test).
- increased citrullination may also offer additional direct contributions to disease pathogenesis through its ability to affect directly the function of several joint and inflammatory mediators (e.g. fibrinogen, anti-thrombin, multiple chemokines).
- anti-PAD4 antibodies can be measured and may correlate with a more erosive form of the disease.
- PAD4 inhibitors are also useful for the reduction of pathological neutrophil activity in a variety of diseases.
- NET Neutrophil Extracellular Trap
- PAD4 inhibitors may therefore have applicability for diseases where NET formation in tissues contributes to local injury and disease pathology.
- Such diseases include, but are not limited to, small vessel vasculitis (Kessenbrock K. et al, Nat. Med., 15(6), (2009), 623-625), systemic lupus erythematosus (Hakkim A. et al, Proc. Natl. Acad. Sci. USA, 107(21), (2010), 9813-9818 and Villanueva E. et al, J. Immunol., 187(1), (2011), 538-52), ulcerative colitis (Savchenko A. et al, Pathol. Int., 61(5), (2011), 290-7), cystic fibrosis, asthma (Dworski R. et al, J. Allergy Clin.
- NETs may contribute to pathology in diseases affecting the skin, eg in cutaneous lupus erythematosis (Villanueva E. et al, J. Immunol., 187(1), (2011), 538-52) and psoriasis (Lin A. M et al., J. Immunol., 187(1), (2011), 490-500), so a PAD4 inhibitor may show benefit to tackle NET skin diseases, when administered by a systemic or cutaneous route. PAD4 inhibitors may affect additional functions within neutrophils and have wider applicability to neutrophilic diseases.
- PAD4 inhibitors are also useful in the treatment of cancers (Slack. J. L. et al, Cell. Mol. Life Sci., 68(4), (2011), 709-720). Over-expression of PAD4 has been demonstrated in numerous cancers (Chang X. et al, BMC Cancer, 9, (2009), 40). An anti-proliferative role has been suggested for PAD4 inhibitors from the observation that PAD4 citrullinates arginine residues in histones at the promoters of p53-target genes such as p21, which are involved in cell cycle arrest and induction of apoptosis (Li P. et al, Mol. Cell Biol., 28(15), (2008), 4745-4758).
- PAD4 is the primary PAD family member observed to be resident in the nucleus as well as the cytoplasm. Early evidence that PAD4 may act as a histone demethyliminase as well as a deiminase is inconsistent and unproven. However, it may reduce histone arginine methylation (and hence epigenetic regulation associated with this mark) indirectly via depletion of available arginine residues by conversion to citrulline. PAD4 inhibitors are useful as epigenetic tools or therapeutics for affecting expression of varied target genes in additional disease settings.
- PAD4 inhibitors may also be effective in controlling citrullination levels in stem cells and may therefore therapeutically affect the pluripotency status and differentiation potential of diverse stem cells including, but not limited to, embryonic stem cells, neural stem cells, haematopoietic stem cells and cancer stem cells. Accordingly, there remains an unmet need to identify and develop PAD4 inhibitors for the treatment of PAD4-mediated disorders.
- a provided compound demonstrates selectivity for PAD4 with respect to PAD2.
- the present invention also provides pharmaceutically acceptable compositions comprising a provided compound.
- Provided compounds are useful in treatment of various disorders associated with PAD4. Such disorders are described in detail, herein, and include, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
- such compounds include those of the formulae described herein, or a pharmaceutically acceptable salt thereof, wherein each variable is as defined herein and described in embodiments.
- Such compounds have the structure of formula I:
- each R 4 is independently selected from
- R 1 is hydrogen or C 1-6 aliphatic
- R 2 is hydrogen or C 1-10 aliphatic
- X is selected from N or CH;
- R 3 is —R, or —OR
- each R is independently hydrogen or C 1-6 aliphatic optionally substituted with 1-3 fluorine atoms.
- aliphatic or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
- aliphatic groups contain 1-6 aliphatic carbon atoms.
- aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
- “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C 3 -C 6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
- Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
- Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
- structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
- structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
- Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
- measurable affinity and “measurably inhibit,” as used herein, means a measurable change in PAD4 activity between a sample comprising a compound of the present invention, or composition thereof, and PAD4, and an equivalent sample comprising PAD4 in the absence of said compound, or composition thereof.
- the present invention provides a compound of formula I:
- each R 4 is independently selected from
- R 1 is hydrogen or C 1-6 aliphatic
- R 2 is hydrogen or C 1-10 aliphatic
- X is selected from N or CH;
- R 3 is —R, or —OR
- each R is independently hydrogen or C 1-6 aliphatic optionally substituted with 1-3 fluorine atoms.
- R 1 is hydrogen, or C 1-6 aliphatic. In some embodiments, R 1 is hydrogen. In some embodiments, R 1 is C 1-6 aliphatic. In some embodiments, R 1 is methyl.
- R 2 is hydrogen or C 1-10 aliphatic. In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is C 1-10 aliphatic. In some embodiments, R 2 is —CH 2 -cyclopropyl.
- R 3 is —R or —OR. In some embodiments, R 3 is —R. In some embodiments, R 3 is —OR. In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is —OCH 3 .
- X is selected from N or CH. In some embodiments, X is N. In some embodiments, X is CH.
- G is
- G is N
- G is N
- G is
- G is N
- G is N
- G is
- G is
- G is N
- G is
- G is
- G is
- G is R
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is selected from
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- G is N
- each R 4 is independently selected from
- R 4 is
- R 4 is
- R 4 is
- R 4 is
- R 4 is
- the compound of formula I is selected from those depicted below in Table 1.
- the present invention provides any compound described above and herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a compound as depicted in Table 1, above, or a pharmaceutically acceptable salt thereof.
- the present invention provides a conjugate comprising PAD4 having a cysteine residue, Cys645, wherein the Cys645 is covalently, and irreversibly, bonded to an inhibitor described above and herein, such that inhibition of the PAD4 is maintained.
- the present invention provides a conjugate of formula X:
- the present invention provides a conjugate of formula X-a:
- the present invention provides a conjugate of formula X-b:
- the present invention provides a conjugate of formula X-c:
- the present invention provides a conjugate of formula X-d:
- the present invention provides a conjugate of formula X-e:
- the present invention provides a conjugate of formula X-f:
- the present invention provides a conjugate of formula X-g:
- the present invention provides a conjugate of formula X-h:
- the present invention provides a conjugate of formula X-i:
- a Modifier of the present invention is a bivalent group resulting from covalent bonding of a Warhead Group with the Cys645 of PAD4. It will be understood that the exemplary modifiers below are shown as conjugated to the sulfhydryl of Cys645 of PAD4.
- the invention provides a composition comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
- the amount of compound in compositions of this invention is such that is effective to measurably inhibit PAD4, in a biological sample or in a patient.
- the amount of compound in compositions of this invention is such that is effective to measurably inhibit PAD4, in a biological sample or in a patient.
- a composition of this invention is formulated for administration to a patient in need of such composition.
- a composition of this invention is formulated for oral administration to a patient.
- a subject is used interchangeably with the term “patient” and means an animal, preferably a mammal.
- a subject or patient is a human.
- a subject (or patient) is a veterinary subject (or patient).
- a veterinary subject (or patient) is a canine, a feline, or an equine subject.
- compositions of this invention refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
- Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block
- compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
- the compositions are administered orally, intraperitoneally or intravenously.
- Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
- a non-toxic parenterally acceptable diluent or solvent for example as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or di-glycerides.
- Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
- These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
- Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
- carriers commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, are also typically added.
- useful diluents include lactose and dried cornstarch.
- aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
- compositions of this invention may be administered in the form of suppositories for rectal administration.
- suppositories for rectal administration.
- suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
- compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
- Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
- compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
- Carriers for topical administration of compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
- provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
- the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
- compositions of this invention may also be administered by nasal aerosol or inhalation.
- Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.
- compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
- the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
- Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- the oral compositions can also include adjuvants such as, for example, water or other solvents, solubil
- sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- the rate of compound release can be controlled.
- biodegradable polymers include poly(orthoesters) and poly(anhydrides).
- Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
- compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and gly
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
- the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
- Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
- the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- buffering agents include polymeric substances and waxes.
- Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
- the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
- Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention.
- the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
- Such dosage forms can be made by dissolving or dispensing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
- compositions of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration.
- provided compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
- a compound of the current invention can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds.
- a compound of the current invention can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.
- Those additional agents may be administered separately from an inventive compound-containing composition, as part of a multiple dosage regimen.
- those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.
- the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention.
- a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.
- the present invention provides a single unit dosage form comprising a compound of the current invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
- compositions of this invention should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of an inventive compound can be administered.
- compositions which comprise an additional therapeutic agent that additional therapeutic agent and the compound of this invention may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent.
- the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
- the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
- a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
- the amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
- the activity of a compound utilized in this invention as an inhibitor of PAD4, may be assayed in vitro, in vivo or in a cell line.
- In vitro assays include assays that determine the inhibition of PAD4.
- Detailed conditions for assaying a compound utilized in this invention as an inhibitor of PAD4 are set forth in the Examples below.
- a provided compound inhibits PAD4 selectively as compared to PAD2.
- treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
- treatment may be administered after one or more symptoms have developed.
- treatment may be administered in the absence of symptoms.
- treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
- the present invention provides a method for treating a PAD4-mediated disorder comprising the step of administering to a patient in need thereof a compound of the present invention, or pharmaceutically acceptable composition thereof.
- a PAD4-mediated disorder is a disease, condition, or disorder mediated by inappropriate PAD4 activity.
- a PAD4-mediated disorder is selected from the group consisting of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
- the disorder mediated by inappropriate PAD4 activity is rheumatoid arthritis.
- the disorder mediated by inappropriate PAD4 activity is systemic lupus.
- the disorder mediated by inappropriate PAD4 activity is vasculitis.
- the disorder mediated by inappropriate PAD4 activity is cutaneous lupus erythematosis.
- the disorder mediated by inappropriate PAD4 activity is psoriasis.
- a method of treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound or a pharmaceutically acceptable salt thereof.
- a method of treatment of rheumatoid arthritis comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof.
- a method of treatment of systemic lupus which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof.
- a method of treatment of vasculitis which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof.
- a method of treatment of cutaneous lupus erythematosis which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof.
- a method of treatment of psoriasis which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof.
- a PAD4-mediated disorder is selected from the group consisting of acid-induced lung injury, acne (PAPA), acute lymphocytic leukemia, acute, respiratory distress syndrome, Addison's disease, adrenal hyperplasia, adrenocortical insufficiency, ageing, AIDS, alcoholic hepatitis, alcoholic hepatitis, alcoholic liver disease, allergen induced asthma, allergic bronchopulmonary, aspergillosis, allergic conjunctivitis, alopecia, Alzheimer's disease, amyloidosis, amyotropic lateral sclerosis, and weight loss, angina pectoris, angioedema, anhidrotic ecodermal dysplasia-ID, ankylosing spondylitis, anterior segment, inflammation, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, asthma, atherosclerosis, atopic dermatitis, autoimmune diseases, autoimmune hepatitis, bee
- PAPA
- the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in therapy. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder mediated by inappropriate PAD4 activity. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis.
- the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of rheumatoid arthritis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of systemic lupus. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of vasculitis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of cutaneous lupus erythematosis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of psoriasis.
- the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PAD4 activity.
- the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis.
- the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of rheumatoid arthritis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of systemic lupus. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of vasculitis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cutaneous lupus erythematosis.
- the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of psoriasis.
- the invention provides a pharmaceutical composition for the treatment or prophylaxis of a disorder mediated by inappropriate PAD4 activity comprising a provided compound, or a pharmaceutically acceptable salt thereof.
- the invention provides a pharmaceutical composition for the treatment or prophylaxis of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis, comprising a provided compound, or a pharmaceutically acceptable salt thereof.
- the invention provides a pharmaceutical composition for the treatment or prophylaxis of rheumatoid arthritis comprising a provided compound, or a pharmaceutically acceptable salt thereof.
- the invention provides a pharmaceutical composition for the treatment or prophylaxis of systemic lupus comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of vasculitis comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of cutaneous lupus erythematosis comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of psoriasis comprising a provided compound, or a pharmaceutically acceptable salt thereof.
- METCR 1410 (low pH Shimadzu 2 min method) Column: Kinetex Core-Shell C18, 2.1 mm ⁇ 50 mm, 5 ⁇ m column Flow rate: 1.2 mL/min Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid (acetonitrile) 0.1%
- reaction mixture was diluted with EtOAc (10 ml) and washed with water (5 ml). The aqueous layer was re-extracted with EtOAc (5 ml). The EtOAc layers were combined, washed with saturated aqueous sodium chloride (5 ml), dried over sodium sulfate, filtered and concentrated in vacuo.
- trans-rac-tert-butyl (3R,4R)-3- ⁇ 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido ⁇ -4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidine-1-carboxylate was purified by chiral HPLC (method E) to obtain 35 mg of trans-tert-butyl (3S,4S)-3- ⁇ 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido ⁇ -4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidine-1-carboxylate EV-AU3235-001 (absolute stereochemistry arbitrarily assigned) and 39 mg of trans-tert
- EV-AU3282-001 (EOAI3449646, I-1) was synthesised according to the procedures described in Scheme 1.3, steps 1 to 8, from tert-butyl 3- ⁇ 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido ⁇ -4-hydroxypyrrolidine-1-carboxylate EV-AU3248-001 synthesised as described in Scheme 1.2:
- EV-AU3261-001 (EOAI3449030, I-3) was synthesised according to the procedures described in Scheme 1.4, steps 1 to 10, using intermediate methyl 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylate EV-AR6658-001 synthesised as described in Scheme 1:
- reaction was quenched with saturated aqueous sodium bicarbonate (10 ml) and extracted with DCM (10 ml). The aqueous layer was washed with DCM (10 ml), the combined organic extracts were dried over sodium sulfate, filtered and concentrated under vacuum.
- reaction mixture was stirred for 24 h, quenched with saturated aqueous sodium thiosulfate (10 ml) and extracted with DCM (3 ⁇ 20 ml). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo.
- N-methyl-1-phenylmethanamine 41 ⁇ l, 0.32 mmol
- sodium triacetoxyborohydride STAB, 51 mg, 0.24 mmol
- acetic acid 10 ⁇ l, 0.17 mmol
- the reaction mixture was filtered and the molecular sieves were washed with DCM (20 ml).
- the DCM solution was washed with saturated aqueous sodium bicarbonate (15 ml) and the aqueous was re-extracted with DCM (3 ⁇ 15 ml).
- the combined organics were washed with saturated aqueous sodium chloride (15 ml), dried over magnesium sulfate and concentrated in vacuo.
- Table 2 shows the activity of selected compounds of this invention in the PAD4 assays described above.
- the compound numbers correspond to the compound numbers in Table 1.
- Compounds having an activity designated as “A” provided an IC 50 of 0.1-1 ⁇ M; compounds having an activity designated as “B” provided an IC 50 of 1-5 ⁇ M; compounds having an activity designated as “C” provided an IC 50 of 5-10 ⁇ M; and compounds having an activity designated as “D” provided an IC 50 of >10 ⁇ M.
- the term pIC 50 ⁇ log(IC 50 ).
- Mass spectrometry was used to analyze covalent modification of protein by selected inhibitors.
- Recombinant human PAD4 was used at 4 mg/ml in 20 mM Tris pH7.6, 400 mM NaCl, 5 mM TCEP. Where applicable, buffer was supplemented with 5 mM CaCl 2 ) to determine Calcium sensitivity of modification.
- Inhibitors were dissolved in DMSO at final concentrations of 0.2 mM to 5 mM and incubated with protein at 27° C. for 16 hours prior to analysis. Control experiments were performed with protein and DMSO in absence of inhibitor.
- Samples were centrifuged for 15 seconds at 10000 rpm at room temperature immediately prior to analysis using a Waters LCT-Premier TOF mass spectrometer, using a mobile phase from 5% to 80% acetonitrile in water supplemented by 0.1% formic acid.
- Covalent binding of an active compound to the target enzyme leads to time dependent loss of the enzyme activity.
- the rate of inactivation depends on the inhibitor concentration ([I]) and can be quantified under pseudo-first order conditions ([I]>>[hPAD4]).
- the inactivation solution was diluted 10-fold in enzymatic reaction buffer (100 mM Tris-HCl, pH 7.6) containing 166.7 ⁇ M peptide substrate (H-TSTGGRQGSHH-CONH 2 ), 1.1 mM CaCl 2 and 2 mM DTT. After 30 minutes of incubation at 37° C. the enzymatic reaction was quenched by 3-fold dilution in 5% TCA solution in ACN. Substrate peptide arginine citrullination was determined by solid phase extraction mass spectrometry (SPE-MS).
- SPE-MS solid phase extraction mass spectrometry
- An Agilent RapidFire 300 equipped with a HILIC (H1) cartridge was used for sampling with solvents 0.1% TFA in H 2 O/ACN (20/80) for P1 and 0.1% TFA in H 2 O/ACN (50/50) for P2 and P3.
- Substrate and product peptide were detected using a coupled Agilent 6460 QQQ and multiple reaction monitoring (MRM) on transitions 562.3/969.4 and 562.8/541, respectively, in positive ion mode.
- DMSO content of the inactivation reaction was 1%.
- Cl-amidine (100 mM, final concentration during enzyme inactivation reaction) and 1% DMSO were used as positive and negative controls of the inactivation reaction, respectively.
- a plot of the pseudo-first order rate constants versus molar concentrations of the inhibitors allowed determination of the kinetic reaction constants: k inact —maximum rate of inactivation at infinite [I]; K I —inhibitor concentration, at which rate of inactivation is equal to 1 ⁇ 2k inact ; k inact /K I .
- Certain compounds of the present invention were assayed according to the procedures described above and were found to covalently modify PAD4.
- Table 3 shows the activity of selected compounds of this invention in the covalent modification assay described above.
- the compound numbers correspond to the compound numbers in Table 1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
Abstract
Description
- PAD4 is a member of the peptidylarginine deiminase (PAD) family of enzymes capable of catalysing the citrullination of arginine into citrulline within peptide sequences. PAD4 is responsible for the deimination or citrullination of a variety of proteins in vitro and in vivo, with consequences of diverse functional responses in a variety of diseases (Jones J. E. et al, Curr. Opin. Drug Discov. Devel., 12(5), (2009), 616-627). Examples of exemplar diseases include rheumatoid arthritis, diseases with neutrophilic contributions to pathogenesis (for example vasculitis, systemic lupus erythematosus, ulcerative colitis) in addition to oncology indications. PAD4 inhibitors also have wider applicability as tools and therapeutics for human disease through epigenetic mechanisms.
- Inhibitors of PAD4 have utility against Rheumatoid Arthritis (RA). RA is an auto-immune disease affecting approximately 1% of the population (Wegner N. et al, Immunol. Rev., 233(1) (2010), 34-54). It is characterised by inflammation of articular joints leading to debilitating destruction of bone and cartilage. A weak genetic association between PAD4 polymorphisms and susceptibility to RA has been suggested, albeit inconsistently, in a number of population studies (Kochi Y. et al, Ann. Rheum. Dis., 70, (2011), 512-515). PAD4 (along with family member PAD2) has been detected in synovial tissue where it is responsible for the deimination of a variety of joint proteins. This process is presumed to lead to a break of tolerance to, and initiation of immune responses to, citrullinated substrates such as fibrinogen, vimentin and collagen in RA joints. These anti-citrullinated protein antibodies (ACPA) contribute to disease pathogenesis and may also be used as a diagnostic test for RA (e.g. the commercially available CCP2 or cyclic citrullinated protein 2 test). In addition, increased citrullination may also offer additional direct contributions to disease pathogenesis through its ability to affect directly the function of several joint and inflammatory mediators (e.g. fibrinogen, anti-thrombin, multiple chemokines). In a smaller subset of RA patients, anti-PAD4 antibodies can be measured and may correlate with a more erosive form of the disease.
- PAD4 inhibitors are also useful for the reduction of pathological neutrophil activity in a variety of diseases. Studies suggest that the process of Neutrophil Extracellular Trap (NET) formation, an innate defence mechanism by which neutrophils are able to immobilise and kill pathogens, is associated with histone citrulllination and is deficient in PAD4 knockout mice (Neeli I. et al, J. Immunol., 180, (2008), 1895-1902 and Li P. et al, J. Exp. Med., 207(9), (2010), 1853-1862). PAD4 inhibitors may therefore have applicability for diseases where NET formation in tissues contributes to local injury and disease pathology. Such diseases include, but are not limited to, small vessel vasculitis (Kessenbrock K. et al, Nat. Med., 15(6), (2009), 623-625), systemic lupus erythematosus (Hakkim A. et al, Proc. Natl. Acad. Sci. USA, 107(21), (2010), 9813-9818 and Villanueva E. et al, J. Immunol., 187(1), (2011), 538-52), ulcerative colitis (Savchenko A. et al, Pathol. Int., 61(5), (2011), 290-7), cystic fibrosis, asthma (Dworski R. et al, J. Allergy Clin. Immunol., 127(5), (2011), 1260-6), deep vein thrombosis (Fuchs T et al, Proc. Natl. Acad. Sci. USA, 107(36), (2010), 15880-5), periodontitis (Vitkov L. et al, Ultrastructural Pathol., 34(1), (2010), 25-30), sepsis (Clark S. R. et al, Nat. Med., 13(4), (2007), 463-9), appendicitis (Brinkmann V. et al, Science, 303, (2004), 1532-5), and stroke. In addition, there is evidence that NETs may contribute to pathology in diseases affecting the skin, eg in cutaneous lupus erythematosis (Villanueva E. et al, J. Immunol., 187(1), (2011), 538-52) and psoriasis (Lin A. M et al., J. Immunol., 187(1), (2011), 490-500), so a PAD4 inhibitor may show benefit to tackle NET skin diseases, when administered by a systemic or cutaneous route. PAD4 inhibitors may affect additional functions within neutrophils and have wider applicability to neutrophilic diseases.
- Studies have demonstrated efficacy of tool PAD inhibitors (for example chloro-amidine) in a number of animal models of disease, including collagen-induced arthritis (Willis VC. et al, J. Immunol., 186(7), (2011), 4396-4404), dextran sulfate sodium (DSS)-induced experimental colitis (Chumanevich A. A. et al, Am. J. Physiol. Gastrointest. Liver Physiol., 300(6), (2011), G929-G938), spinal cord repair (Lange S. et al, Dev. Biol., 355(2), (2011), 205-14), and experimental autoimmune encephalomyelitis (EAE). The DSS colitis report also demonstrates that chloro-amidine drives apoptosis of inflammatory cells both in vitro and in vivo, suggesting that PAD4 inhibitors may be effective more generally in widespread inflammatory diseases.
- PAD4 inhibitors are also useful in the treatment of cancers (Slack. J. L. et al, Cell. Mol. Life Sci., 68(4), (2011), 709-720). Over-expression of PAD4 has been demonstrated in numerous cancers (Chang X. et al, BMC Cancer, 9, (2009), 40). An anti-proliferative role has been suggested for PAD4 inhibitors from the observation that PAD4 citrullinates arginine residues in histones at the promoters of p53-target genes such as p21, which are involved in cell cycle arrest and induction of apoptosis (Li P. et al, Mol. Cell Biol., 28(15), (2008), 4745-4758).
- The aforementioned role of PAD4 in deiminating arginine residues in histones may be indicative of a role for PAD4 in epigenetic regulation of gene expression. PAD4 is the primary PAD family member observed to be resident in the nucleus as well as the cytoplasm. Early evidence that PAD4 may act as a histone demethyliminase as well as a deiminase is inconsistent and unproven. However, it may reduce histone arginine methylation (and hence epigenetic regulation associated with this mark) indirectly via depletion of available arginine residues by conversion to citrulline. PAD4 inhibitors are useful as epigenetic tools or therapeutics for affecting expression of varied target genes in additional disease settings. Through such mechanisms, PAD4 inhibitors may also be effective in controlling citrullination levels in stem cells and may therefore therapeutically affect the pluripotency status and differentiation potential of diverse stem cells including, but not limited to, embryonic stem cells, neural stem cells, haematopoietic stem cells and cancer stem cells. Accordingly, there remains an unmet need to identify and develop PAD4 inhibitors for the treatment of PAD4-mediated disorders.
- It has now been found that compounds of formula I are useful as inhibitors of PAD4:
- or a pharmaceutically acceptable salt thereof, wherein each of G, R1, R2, R3 and X is as defined and described herein.
- In some embodiments, a provided compound demonstrates selectivity for PAD4 with respect to PAD2. The present invention also provides pharmaceutically acceptable compositions comprising a provided compound. Provided compounds are useful in treatment of various disorders associated with PAD4. Such disorders are described in detail, herein, and include, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
- In some embodiments, such compounds include those of the formulae described herein, or a pharmaceutically acceptable salt thereof, wherein each variable is as defined herein and described in embodiments. Such compounds have the structure of formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
-
- each R4 is independently selected from
- R1 is hydrogen or C1-6 aliphatic;
R2 is hydrogen or C1-10 aliphatic;
X is selected from N or CH; - each R is independently hydrogen or C1-6 aliphatic optionally substituted with 1-3 fluorine atoms.
- Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
- The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
- As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
- Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
- The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change in PAD4 activity between a sample comprising a compound of the present invention, or composition thereof, and PAD4, and an equivalent sample comprising PAD4 in the absence of said compound, or composition thereof.
- According to one aspect, the present invention provides a compound of formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- each R4 is independently selected from
- R1 is hydrogen or C1-6 aliphatic;
R2 is hydrogen or C1-10 aliphatic;
X is selected from N or CH; - each R is independently hydrogen or C1-6 aliphatic optionally substituted with 1-3 fluorine atoms.
- As defined above and described herein, R1 is hydrogen, or C1-6 aliphatic. In some embodiments, R1 is hydrogen. In some embodiments, R1 is C1-6 aliphatic. In some embodiments, R1 is methyl.
- As defined above and described herein, R2 is hydrogen or C1-10 aliphatic. In some embodiments, R2 is hydrogen. In some embodiments, R2 is C1-10 aliphatic. In some embodiments, R2 is —CH2-cyclopropyl.
- In some embodiments, R3 is —R or —OR. In some embodiments, R3 is —R. In some embodiments, R3 is —OR. In some embodiments, R3 is hydrogen. In some embodiments, R3 is —OCH3.
- As defined above and described herein, X is selected from N or CH. In some embodiments, X is N. In some embodiments, X is CH.
- As defined above and described herein, G is
- In some embodiments, G is
- In some embodiments, G is
- In other embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In other embodiments, G is
- In certain embodiments, G is
- In some embodiments, G is
- In other embodiments, G is
- In certain embodiments, G is
- In some embodiments. G is
- In some embodiments, G is R
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is selected from
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- In some embodiments, G is
- As defined above and described herein, each R4 is independently selected from
- In some embodiments, R4 is
- In some embodiments, R4 is
- In some embodiments, R4 is
- In some embodiments, R4 is
- In some embodiments,
- In some embodiments, R4 is
- In some embodiments, the compound of formula I is selected from those depicted below in Table 1.
- In certain embodiments, the present invention provides any compound described above and herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a compound as depicted in Table 1, above, or a pharmaceutically acceptable salt thereof.
- In certain embodiments, the present invention provides a conjugate comprising PAD4 having a cysteine residue, Cys645, wherein the Cys645 is covalently, and irreversibly, bonded to an inhibitor described above and herein, such that inhibition of the PAD4 is maintained.
- In certain embodiments, the present invention provides a conjugate of formula X:
- wherein:
- Cys645 is cysteine 645 of PAD4;
- Modifier is a bivalent group resulting from covalent bonding of a Warhead Group with the Cys645 of the PAD4; and
- Warhead Group is a functional group on G capable of covalently binding to the Cys645 of the PAD4.
- In some embodiments, the present invention provides a conjugate of formula X-a:
- wherein each of Cys645, Modifier, R1, R2, R3, and X is as defined above and described herein.
- In some embodiments, the present invention provides a conjugate of formula X-b:
- wherein each of Cys645, Modifier, R1, R2, R3, and X is as defined above and described herein.
- In some embodiments, the present invention provides a conjugate of formula X-c:
- wherein each of Cys645, Modifier, R1, R2, R3, and X is as defined above and described herein.
- In some embodiments, the present invention provides a conjugate of formula X-d:
- wherein each of Cys645, Modifier, R1, R2, R3, and X is as defined above and described herein.
- In some embodiments, the present invention provides a conjugate of formula X-e:
- wherein each of Cys645, Modifier, R1, R2, R3, and X is as defined above and described herein.
- In some embodiments, the present invention provides a conjugate of formula X-f:
- wherein each of Cys645, Modifier, R1, R2, R3, and X is as defined above and described herein.
- In some embodiments, the present invention provides a conjugate of formula X-g:
- wherein each of Cys645, Modifier, R1, R2, R3, and X is as defined above and described herein.
- In some embodiments, the present invention provides a conjugate of formula X-h:
- wherein each of Cys645, Modifier, R1, R2, R3, and X is as defined above and described herein.
- In some embodiments, the present invention provides a conjugate of formula X-i:
- wherein each of Cys645, Modifier, R1, R2, R3, and X is as defined above and described herein.
- A Modifier of the present invention is a bivalent group resulting from covalent bonding of a Warhead Group with the Cys645 of PAD4. It will be understood that the exemplary modifiers below are shown as conjugated to the sulfhydryl of Cys645 of PAD4.
- Pharmaceutically Acceptable Compositions
- According to another embodiment, the invention provides a composition comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in compositions of this invention is such that is effective to measurably inhibit PAD4, in a biological sample or in a patient. In certain embodiments, the amount of compound in compositions of this invention is such that is effective to measurably inhibit PAD4, in a biological sample or in a patient. In certain embodiments, a composition of this invention is formulated for administration to a patient in need of such composition. In some embodiments, a composition of this invention is formulated for oral administration to a patient.
- The term “subject,” as used herein, is used interchangeably with the term “patient” and means an animal, preferably a mammal. In some embodiments, a subject or patient is a human. In other embodiments, a subject (or patient) is a veterinary subject (or patient). In some embodiments, a veterinary subject (or patient) is a canine, a feline, or an equine subject.
- The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
- Compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- Pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
- Alternatively, pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
- Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
- Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
- For topical applications, provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
- Pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- Most preferably, pharmaceutically acceptable compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.
- Pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
- Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
- Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
- Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
- Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
- The amount of compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, provided compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
- A compound of the current invention can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds. A compound of the current invention can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.
- Those additional agents may be administered separately from an inventive compound-containing composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.
- As used herein, the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a compound of the current invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
- The amount of both an inventive compound and additional therapeutic agent (in those compositions which comprise an additional therapeutic agent as described above) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, compositions of this invention should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of an inventive compound can be administered.
- In those compositions which comprise an additional therapeutic agent, that additional therapeutic agent and the compound of this invention may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent.
- The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
- It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
- Uses of Compounds and Pharmaceutically Acceptable Compositions
- Compounds and compositions described herein are generally useful for the inhibition of PAD4.
- The activity of a compound utilized in this invention as an inhibitor of PAD4, may be assayed in vitro, in vivo or in a cell line. In vitro assays include assays that determine the inhibition of PAD4. Detailed conditions for assaying a compound utilized in this invention as an inhibitor of PAD4 are set forth in the Examples below. In some embodiments, a provided compound inhibits PAD4 selectively as compared to PAD2.
- As used herein, the terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
- Provided compounds are inhibitors of PAD4 and are therefore useful for treating one or more disorders associated with activity of PAD4. Thus, in certain embodiments, the present invention provides a method for treating a PAD4-mediated disorder comprising the step of administering to a patient in need thereof a compound of the present invention, or pharmaceutically acceptable composition thereof.
- In one embodiment, a PAD4-mediated disorder is a disease, condition, or disorder mediated by inappropriate PAD4 activity. In some embodiments, a PAD4-mediated disorder is selected from the group consisting of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is rheumatoid arthritis. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is systemic lupus. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is vasculitis. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is cutaneous lupus erythematosis. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is psoriasis.
- In one embodiment there is provided a method of treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound or a pharmaceutically acceptable salt thereof.
- In one embodiment there is provided a method of treatment of rheumatoid arthritis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of treatment of systemic lupus, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of treatment of vasculitis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of treatment of cutaneous lupus erythematosis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of treatment of psoriasis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof.
- In some embodiments, a PAD4-mediated disorder is selected from the group consisting of acid-induced lung injury, acne (PAPA), acute lymphocytic leukemia, acute, respiratory distress syndrome, Addison's disease, adrenal hyperplasia, adrenocortical insufficiency, ageing, AIDS, alcoholic hepatitis, alcoholic hepatitis, alcoholic liver disease, allergen induced asthma, allergic bronchopulmonary, aspergillosis, allergic conjunctivitis, alopecia, Alzheimer's disease, amyloidosis, amyotropic lateral sclerosis, and weight loss, angina pectoris, angioedema, anhidrotic ecodermal dysplasia-ID, ankylosing spondylitis, anterior segment, inflammation, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, asthma, atherosclerosis, atopic dermatitis, autoimmune diseases, autoimmune hepatitis, bee sting-induced inflammation, behcet's disease, Behcet's syndrome, Bells Palsey, berylliosis, Blau syndrome, bone pain, bronchiolitis, burns, bursitis, cancer, cardiac hypertrophy, carpal tunnel syndrome, catabolic disorders, cataracts, cerebral aneurysm, chemical irritant-induced inflammation, chorioretinitis, chronic heart failure, chronic lung disease of prematurity, chronic lymphocytic leukemia, chronic obstructive pulmonary disease, colitis, complex regional pain syndrome, connective tissue disease, corneal ulcer, crohn's disease, cryopyrin-associated periodic syndromes, cyrptococcosis, cystic fibrosis, deficiency of the interleukin-1-receptor antagonist (DIRA), dermatitis, dermatitis endotoxemia, dermatomyositis, diffuse intrinsic pontine glioma, endometriosis, endotoxemia, epicondylitis, erythroblastopenia, familial amyloidotic polyneuropathy, familial cold urticarial, familial mediterranean fever, fetal growth retardation, glaucoma, glomerular disease, glomerular nephritis, gout, gouty arthritis, graft-versus-host disease, gut diseases, head injury, headache, hearing loss, heart disease, hemolytic anemia, Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome, herpes zoster and simplex, HIV-1, Hodgkin's disease, Huntington's disease, hyaline membrane disease, hyperammonemia, hypercalcemia, hypercholesterolemia, hyperimmunoglobulinemia D with recurrent fever (HIDS), hypoplastic and other anemias, hypoplastic anemia, idiopathic thrombocytopenic purpura, incontinentia pigmenti, infectious mononucleosis, inflammatory bowel disease, inflammatory lung disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation, iritis, irritant-induced inflammation, ischemia/reperfusion, juvenile rheumatoid arthritis, keratitis, kidney disease, kidney injury caused by parasitic infections, kidney injury caused by parasitic infections, kidney transplant rejection prophylaxis, leptospiriosis, leukemia, Loeffler's syndrome, lung injury, lung injury, lupus, lupus, lupus nephritis, lymphoma, meningitis, mesothelioma, mixed connective tissue disease, Muckle-Wells syndrome (urticaria deafness amyloidosis), multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis, myocarditis, mycosis fungiodes, mycosis fungoides, myelodysplastic syndrome, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset multisystem inflammatory disease (NOMID), nephrotic syndrome, neuritis, neuropathological diseases, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant, osterarthritis, otitis media, paget's disease, pain, pancreatitis, Parkinson's disease, pemphigus, pericarditis, periodic fever, periodontitis, peritoneal endometriosis, pertussis, pharyngitis and adenitis (PFAPA syndrome), plant irritant-induced inflammation, pneumonia, pneumonitis, pneumosysts infection, poison ivy/urushiol oil-induced inflammation, polyarteritis nodosa, polychondritis, polycystic kidney disease, polymyositis, psoriasis, psoriasis, psoriasis, psoriasis, psychosocial stress diseases, pulmonary disease, pulmonary hypertension, pulmonayr fibrosis, pyoderma gangrenosum, pyogenic sterile arthritis, renal disease, retinal disease, rheumatic carditis, rheumatic disease, rheumatoid arthritis, sarcoidosis, seborrhea, sepsis, severe pain, sickle cell, sickle cell anemia, silica-induced disease, Sjogren's syndrome, skin diseases, sleep apnea, solid tumors, spinal cord injury, Stevens-Johnson syndrome, stroke, subarachnoid hemorrhage, sunburn, temporal arteritis, tenosynovitis, thrombocytopenia, thyroiditis, tissue transplant, TNF receptor associated periodic syndrome (TRAPS), toxoplasmosis, transplant, traumatic brain injury, tuberculosis, type 1 diabetes, type 2 diabetes, ulcerative colitis, urticarial, uveitis, and Wegener's granulomatosis.
- In one embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in therapy. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder mediated by inappropriate PAD4 activity. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of rheumatoid arthritis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of systemic lupus. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of vasculitis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of cutaneous lupus erythematosis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of psoriasis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PAD4 activity. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of rheumatoid arthritis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of systemic lupus. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of vasculitis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cutaneous lupus erythematosis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of psoriasis. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of a disorder mediated by inappropriate PAD4 activity comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis, comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of rheumatoid arthritis comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of systemic lupus comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of vasculitis comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of cutaneous lupus erythematosis comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of psoriasis comprising a provided compound, or a pharmaceutically acceptable salt thereof
- All features of each of the aspects of the invention apply to all other aspects mutatis mutandis.
- In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
- As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein.
- List of Common Abbreviations Used in the Experimental Section.
-
- AcOH: acetic acid
- (Boc)2O: di-tert-butyl dicarbonate
- Chiral HPLC: chiral high performance liquid chromatography
- DCM: dichloromethane
- Dess Martin Periodinane: 1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one
- DIAD: diisopropyl azodicarboxylate
- DIPEA: N,N-diisopropylethylamine
- DMAP: 4-dimethylaminopyridine
- DMF: N,N-dimethylformamide
- DMSO: dimethyl sulfoxide
- EtOAc: ethyl acetate
- EtOH: ethanol
- HATU: N-[(Dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide
- H-Cube: continuous flow hydrogenation reactor
- HPLC: high performance liquid chromatography
- HCl: hydrochloric acid
- Kieselguhr: diatomaceous earth
- LCMS: Liquid chromatography-mass spectrometry
- M: molar
- Me: methyl
- MeCN: acetonitrile
- MeI: methyl iodide
- min: minutes
- mL: millilitres
- MeOH: methanol
- MsCl: methanesulfonyl chloride
- NaHMDS: sodium bis(trimethylsilyl)amide
- NMR: Nuclear Magnetic Resonance
- ° C.: degrees Celsius
- Pd/C: palladium on carbon
- Pd(OH)2/C: palladium hydroxide on carbon
- prep HPLC: preparative high performance liquid chromatography
- STAB: sodium triacetoxyborohydride
- TBAF: tetrabutylammonium fluoride
- TBDMSCl: tert-Butyldimethylsilyl chloride
- TBTU: O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate
- TEA: triethylamine
- TFA: trifluoracetic acid
- THF: tetrahydrofuran
- Tret: retention time
- Preparative HPLC Methods
- Basic HPLC Preparative Method
- Column: XBridge™ Prep. C18 10 um OBD™, 30×100 mm
Mobile Phase: 5-95% Acetonitrile (0.2% ammonium hydroxide) in Water (0.2% ammonium hydroxide) over 14 minutes
Flow Rate: 40 mL/min - Acidic HPLC Preparative Method
- Column: Sunfire™ Prep. C18 10 um OBD™, 30×100 mm
Mobile Phase: 5-95% Acetonitrile (0.1% formic acid) in Water (0.1% formic acid) over 14 minutes
Flow Rate: 40 mL/min - Analytical LCMS Methods:
- Method A
- MET/u-HPLC (MSQ1 low pH 7 min method)
Column: Phenomenex Kinetex-XB C18, 2.1 mm×100 mm, 1.7 μm
Flow rate: 0.6 ml/min
Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid (MeCN) 0.1% - Detection: 215 nm (nominal)
Gradient Time (minutes)-% B
0.00-5
5.30-100
5.80-100
5.82-5 - Method B
- MET/CR/1600 (MS10 high pH 7 min method)
Column: Phenomenex Gemini C18, 2.0 mm×100 mm, 3 μm
Flow rate: 0.5 mL/min
Mobile phase: A, 2 mM ammonium bicarbonate in HPLC grade water pH10 -
- B HPLC grade MeCN
Injection volume: 3 μL
- B HPLC grade MeCN
- Gradient time: (minutes)-% B
0.0-5
5.50-100
5.90-100
5.92-5
9.00-5 - Method C
- METCR 1416 (low pH Shimadzu 7 min method)
Column: Waters Atlantis dC18, 2.1 mm×100 mm, 3 μm column
Flow rate: 0.6 mL/min
Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid (acetonitrile) 0.1% - Detection: 215 nm (nominal)
Gradient Time (minutes)-% B
0.00-5
5.00-100
5.40-100
5.42-5 - Method D
- METCR 1410 (low pH Shimadzu 2 min method)
Column: Kinetex Core-Shell C18, 2.1 mm×50 mm, 5 μm column
Flow rate: 1.2 mL/min
Mobile Phase: A, Formic acid (aqueous) 0.1% and B, Formic acid (acetonitrile) 0.1% - Detection: 215 nm (nominal)
Gradient Time (minutes)-% B
0.00-5
1.20-100
1.30-100
1.31-5 - Method H
- MET/u-HPLC (high pH MS16 7 min method)
Column: Waters UPLC CSH C18, 2.1 mm×100 mm 5 μm column
Flow rate: 0.6 mL/min
Mobile Phase: A, 2 mM Ammonium bicarbonate modified to pH 10 with Ammonium hydroxide (aqueous) and B, acetonitrile - Detection: 215 nm (nominal)
Gradient Time (minutes)-% B
0.00-5
5.30-100
5.80-100
5.82-5 - Method J
- MET/CR/0990 (high pH 3 min method)
Column: Phenomenex Gemini C18, 2.0 mm×100 mm, 3 μm
Flow rate: 1 mL/min
Mobile phase: A, 2 mM ammonium bicarbonate in HPLC grade water pH10 -
- B HPLC grade MeCN
Injection volume: 3 μL
- B HPLC grade MeCN
- Gradient time: (minutes)-% B
0.0-1
1.80-100
2.10-100
2.30-1 - Analytical and Preparative Chiral HPLC Methods:
- Method E:
- Chiral HPLC preparative method
Column: Lux C1 (21.2 mm×250 mm, 5 μm)
Flow rate: 50 mL/min - Method F:
- Chiral purity analysis method
Column: Lux C1 (4.6 mm×250 mm, 5 um)
Flow Rate: 4 mL/min - Certain compounds of the present invention were prepared according to Scheme 1, steps 1 to 9, below.
-
- To a stirred solution of ethyl 1H-pyrrolo[2,3-b]pyridine-2-carboxylate (CAS 221675-35-0, 4.40 g, 23.1 mmol) in DMF (50 ml) was added sodium hydride (60%, 1.05 g, 26.3 mmol). The mixture was stirred under nitrogen at room temperature for 45 minutes and (bromomethyl)cyclopropane (CAS 7051-34-5, 2.70 ml, 27.8 mmol) was added. The mixture was stirred at room temperature for 2.5 h and the solvent was removed in vacuo. The residue was suspended in THF (40 ml) and 5M aqueous sodium hydroxide (22 ml, 110 mmol) was added. The mixture was stirred at 50° C. for 3.5 h. Additional THF (20 ml) and 5M aqueous sodium hydroxide (22 ml, 110 mmol) were added and the reaction was stirred at 50° C. for 16 h. The reaction crude was concentrated in vacuo and water (10 ml) and 5M aqueous hydrochloric acid (100 ml) were added. The solid was filtered off, washed with water (2×100 ml) and dried to obtain 3.46 g (69.2%) of 1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid EV-AR3164-001 as a white powder. LCMS (method D): retention time 1.03 min, M/z=217 (M+1).
- To a stirred solution of methyl 4-fluoro-3-nitrobenzoate (CAS 329-59-9, 5.00 g, 25.1 mmol) in DMF (50 ml) was added methanamine hydrochloride (1:1) (2.00 g, 29.6 mmol) and potassium carbonate (4.50 g, 32.6 mmol). The mixture was stirred at room temperature under nitrogen for 18 h. The reaction crude was concentrated in vacuo and the residue was partitioned between in EtOAc (350 ml) and 1N aqueous hydrochloric acid (250 ml). The organic layer was washed further with 1N aqueous hydrochloric acid (150 ml) and saturated aqueous sodium chloride (100 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo to obtain 5.30 g (quantitative) of methyl 4-(methylamino)-3-nitrobenzoate EV-AR3152-001 as a yellow powder. LCMS (method D): retention time 1.07 min, M/z=211 (M+1).
- To a stirred solution of methyl 4-(methylamino)-3-nitrobenzoate (EV-AR3152-001, 5.30 g, 25.2 mmol) in ethanol (100 ml) under nitrogen was added 10% Pd/C (1.30 g, 0.05 mmol). The reaction was then placed under a hydrogen atmosphere and stirred at room temperature for 4 h. The reaction mixture was diluted with methanol (100 ml) and Kieselguhr was added. The mixture was stirred at room temperature for 10 minutes and filtered under vacuum. The filter was washed with methanol (3×50 ml) and the filtrate was concentrated in vacuo to obtain 4.39 g (96.6%) of methyl 3-amino-4-(methylamino)benzoate EV-AR3155-001 as a brown powder. LCMS (method D): retention time 0.75 min, M/z=181 (M+1).
- To a solution of 1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (EV-AR3164-001, 2.20 g, 10.2 mmol) in dry DMF (40 ml) was added HATU (4.95 g, 12.8 mmol) and DIPEA (2.25 ml, 12.8 mmol). The mixture was stirred at room temperature for 1 h then methyl 3-amino-4-(methylamino)benzoate (EV-AR3155-001, 2.02 g, 11.2 mmol) was added. The mixture was stirred at room temperature for 16 h. The solvent was removed in vacuo and the residue was dissolved in acetic acid (40 ml) and stirred at 80° C. for 2 h, then 85° C. for 30 minutes then 90° C. for 1 h. The solvent was removed in vacuo and the crude material was purified by flash column chromatography (12-100% EtOAc/heptane) to obtain 3.08 g (83.2%) of methyl 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylate EV-AR3167-001 as a pink powder. LCMS (method D): retention time 1.20 min, M/z=361 (M+1).
- To a suspension of methyl 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylate (EV-AR3167-001, 3.08 g, 8.46 mmol) in methanol (60 ml) was added 2M aqueous sodium hydroxide (30 ml, 60.0 mmol). The mixture was then stirred at 50° C. for 2 h. The reaction was allowed to cool to room temperature and the solvent was removed in vacuo. Water (50 ml) was added followed by 2M aqueous HCl until pH 3 was achieved. The mixture was stirred for 15 minutes and filtered through a sinter. The solid was washed with water (2×50 ml) and air-dried for 64 h to afford 1.81 g (61.2%) of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid EV-AR3168-001 as a beige solid. LCMS (method D): retention time 1.05 min, M/z=347 (M+1). The filtrate was further acidified by addition of 2M aqueous HCl until a precipitate started to form. The mixture was allowed to stand for 1 h and filtered through a sinter. The solid was washed with water (2×20 ml) and air-dried under vacuum for 3 h to obtain 460 mg of (15.7%) 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid EV-AR3168-002 as an off white powder LCMS (method D): retention time 1.06 min, M/z=347 (M+1).
- A solution of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid (EV-AQ1914-001, 100 mg, 0.29 mmol) and HATU (121 mg, 0.32 mmol) in dry DMF (2 ml) was treated with DIPEA (55 μL, 0.32 mmol) at room temperature. The mixture was stirred for 1 h then trans-rac-tert-butyl (3R,4R)-3,4-diaminopyrrolidine-1-carboxylate (CAS 1020571-45-2, 58 mg, 0.29 mmol) was added and the reaction mixture stirred at room temperature for 1 h. The reaction mixture was diluted with EtOAc (10 ml), washed with water (5 ml) then saturated aqueous sodium chloride (3 ml). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by column chromatography (1-9% MeOH/DCM) to obtain 40 mg (25%) of trans-rac-tert-butyl (3R,4R)-3-amino-4-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate EV-AE3986-001 as a colourless crystalline solid. LCMS (method D): retention time 0.98 min, M/z=530 (M+1).
- A solution of trans-rac-tert-butyl (3R,4R)-3-amino-4-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate (EV-AE3986-001, 40 mg, 0.08 mmol), (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride (15 mg, 0.091 mmol) and HATU (34 mg, 0.091 mmol) in dry DMF (1 ml) was treated with DIPEA (29 μl, 0.16 mmol) at room temperature and the mixture was stirred for 20 minutes. The reaction mixture was diluted with EtOAc (10 ml) and washed with water (5 ml). The aqueous layer was re-extracted with EtOAc (5 ml). The EtOAc layers were combined, washed with saturated aqueous sodium chloride (5 ml), dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by prep HPLC (acidic method) to obtain 18 mg (34.7%) of trans-rac-formic acid; tert-butyl (3R,4R)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidine-1-carboxylate EV-AE3988-001 as a colourless crystalline solid. LCMS (method D): retention time 1.00 min, M/z=641 (M+1).
- To trans-rac-formic acid; tert-butyl (3R,4R)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidine-1-carboxylate (EV-AE3988-001, 17 mg, 0.03 mmol) was added 2M HCl in ether (0.13 ml, 0.25 mmol) and the mixture was left standing at room temperature for 1 h. Another portion of 2M HCl in ether (0.13 ml) was added and swirled around the reaction vial, then allowed to stand for 30 mins. The reaction mixture was concentrated to dryness and dried in vacuo to obtain 15 mg (97%) of trans-rac-2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,4R)-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidin-3-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxamide dihydrochloride EV-AE3989-001 as an off-white crystalline solid. LCMS (method C): retention time 2.80 min, M/z=541 (M+1).
-
- 115 mg of trans-rac-tert-butyl (3R,4R)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidine-1-carboxylate was purified by chiral HPLC (method E) to obtain 35 mg of trans-tert-butyl (3S,4S)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidine-1-carboxylate EV-AU3235-001 (absolute stereochemistry arbitrarily assigned) and 39 mg of trans-tert-butyl (3R,4R)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidine-1-carboxylate EV-AU3235-002 (absolute stereochemistry arbitrarily assigned).
- EV-AU3235-001 Chiral purity (UV, 254 nm): 100%, retention time: 1.89 min (method F)
EV-AU3235-002 Chiral purity (UV, 254 nm): 99%, retention time: 2.27 min (method F) -
- Tert-butyl (3S,4S)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidine-1-carboxylate (EV-AU3253-001, 35 mg, 0.054 mmol) was treated as in step 8, Scheme 1 to obtain 35 mg (99%) of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-N-[(3S,4S)-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidin-3-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxamide 1-5, EV-AU3253-001, as a white powder. LCMS (method A): retention time 1.43 min, M/z=541 (M+1).
-
- Tert-butyl (3R,4R)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidine-1-carboxylate (EV-AU3254-001, 39 mg, 0.06 mmol) was treated as in step 8, Scheme 1 to obtain 39 mg (98%) of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,4R)-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidin-3-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxamide trihydrochloride 1-4, EV-AU3254-001, as an off-white powder. LCMS (method A): retention time 1.44 min, M/z=541 (M+1).
- Rac-2-[1-(cyclopropylmethyl)-1H-indol-2-yl]-N-[(3R,4R)-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidin-3-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carboxamide EV-AU9306-001 (EOAI3449033, I-2) was synthesised according to the procedures described in Scheme 1 via synthesis of methyl 3-amino-5-methoxy-4-(methylamino)benzoate EV-AR0068-002 as described in Scheme 1.1:
- To a stirred solution of methyl 4-chloro-3-methoxy-5-nitrobenzoate (CAS 63603-09-8, 2.00 g, 8.14 mmol) in DMF (10 ml) was added K2CO3 (99%, 1.37 g, 9.81 mmol). To this solution was added methanamine hydrochloride (1:1) (0.62 g, 9.18 mmol) and the mixture was stirred in a sealed tube under nitrogen at 80° C. for 16 h. The reaction crude was concentrated in vacuo and partitioned between DCM (100 ml) and water (10 ml). The organic layer was washed further with water (2×10 ml) and saturated aqueous sodium chloride (10 ml). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to afford an orange powder which was purified by flash column chromatography (15-40% EtOAc/heptane) to obtain 1.49 g (76%) of methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate EV-AR0065-002 as an orange powder. LCMS (method D): retention time 1.13 min, M/z=241 (M+1).
- To a stirred solution of methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate (EV-AR0065-002, 1.49 g, 6.20 mmol) in ethanol (100 ml) under nitrogen was added 10% Pd/C (0.18 g, 0.17 mmol) and the resulting mixture was stirred at room temperature under an atmosphere of hydrogen for 16 h. The reaction mixture was filtered through Kieselguhr and the filter was washed through with methanol (150 ml). The filtrate was concentrated in vacuo to afford 1.21 g (89%) of methyl 3-amino-5-methoxy-4-(methylamino)benzoate EV-AR0068-002 as a pale purple powder. LCMS (method D): retention time 0.63 min, M/z=211 (M+1).
- Rac-(3R,4S)-4-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidin-3-yl prop-2-enoate EV-AE3981-002 (EOAI3441779, I-11) was synthesised according to the procedures described in Scheme 1.2, steps 1 to 3, from 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid EV-AR3168-002 synthesised as described in Scheme 1:
-
- To a stirred solution of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid (EV-AR3168-002, 100 mg, 0.29 mmol) and HATU (131 mg, 0.35 mmol) in DMF (3 ml) was added DIPEA (60 μl, 0.35 mmol). The resulting mixture was stirred at room temperature for 1 h then cis-rac-tert-butyl(3S,4R)-3-amino-4-hydroxypyrrolidine-1-carboxylate (CAS 138026-97-8, 70 mg, 0.35 mmol) was added and the reaction was continued for 2 h. The reaction was diluted with EtOAc (5 ml) and washed with water (5 ml). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash column chromatography (0-5% MeOH/DCM) to afford 135 mg (84%) of cis-rac-tert-butyl 3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-hydroxypyrrolidine-1-carboxylate EV-AE3975-001 as a tan powder. LCMS (method D): retention time 1.14 min, M/z=531 (M+1).
-
- To a stirred solution of cis-rac-tert-butyl 3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-hydroxypyrrolidine-1-carboxylate (EV-AE3975-001, 50 mg, 0.094 mmol) in DCM (1 ml) was added prop-2-enoyl chloride (CAS 814-68-6, 0.011 ml, 0.14 mmol) and DIPEA (0.025 ml, 0.14 mmol). The mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with DCM (5 ml) and washed with water (2 ml) and brine (2 ml). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash column chromatography (0-3% MeOH/DCM) to obtain 32 mg (58%) of cis-rac-tert-butyl 3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-(prop-2-enoyloxy)pyrrolidine-1-carboxylate EV-AE3979-001 as a colourless oil. LCMS (method D): retention time 1.31 min, M/z=585 (M+1).
-
- 2M HCl in ether (0.23 ml, 0.57 mmol) was added to cis-rac-tert-butyl 3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-(prop-2-enoyloxy)pyrrolidine1carboxylate (EV-AE3979-001, 30 mg, 0.057 mmol) and the resulting mixture was allowed to stand at room temperature for 2 h. The solvent was removed in vacuo and the solid azeotroped with DCM (1 ml). The solvent was removed in vacuo and the solid was dried to obtain 25 mg (83%) of cis-rac-(3R,4S)-4-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidin-3-yl prop-2-enoate hydrochloride EV-AE3981-002 as an off white powder. LCMS (method A): retention time 1.96 min, M/z=485 (M+1).
- Cis-rac-2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,4R)-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidin-3-yl]-N,1-dimethyl-1H-1,3-benzodiazole-5-carboxamide EV-AU3282-001 (EOAI3449646, I-1) was synthesised according to the procedures described in Scheme 1.3, steps 1 to 8, from tert-butyl 3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-hydroxypyrrolidine-1-carboxylate EV-AU3248-001 synthesised as described in Scheme 1.2:
-
- To a stirred solution of cis-rac-tert-butyl (3R,4S)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-4-hydroxypyrrolidine-1-carboxylate (EV-AU3248-001, 820 mg, 1.55 mmol) in DMF (7.5 ml) was added imidazole (158 mg, 2.32 mmol) and TBDMSCl (280 mg, 1.85 mmol). The reaction was stirred at room temperature for 16 h. The reaction was diluted with water (20 ml) and extracted with EtOAc (3×10 ml). The combined organics were washed with water (2×20 ml), dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash column chromatography (50-100% EtOAc/heptanes) to obtain 638 mg (61%) of cis-rac-tert-butyl (3R,4S)-3-[(tert-butyldimethylsilyl)oxy]-4-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate EV-AU3250-001 as a colourless powder. LCMS (method D): retention time 1.55 min, M/z=645 (M+1).
-
- To a stirred solution of cis-rac-tert-butyl (3R,4S)-3-[(tert-butyldimethylsilyl)oxy]-4-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate (EV-AU3250-001, 630 mg, 0.98 mmol) in THF (12 ml) at −78° C. was added 2M NaHMDS in THF (1.47 ml) and the reaction was left to stir for 10 minutes. Iodomethane (0.36 ml, 5.86 mmol) was then added and the reaction was allowed to warm to room temperature while stirring for 3 h. The reaction mixture was diluted with diethyl ether (20 ml), washed with aq saturated sodium bicarbonate (10 ml) and then saturated aqueous sodium chloride (10 ml). The organic extract was then dried with sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by flash column chromatography (40-100% EtOAc/heptanes) to obtain 470 mg (67%) of cis-rac-tert-butyl (3R,4S)-3-[(tert-butyldimethylsilyl)oxy]-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate EV-AU3257-001 as a colourless powder. LCMS (method D): retention time 1.60 min, M/z=659 (M+1).
-
- To a stirred solution of cis-rac-tert-butyl (3R,4S)-3-[(tert-butyldimethylsilyl)oxy]-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate (EV-AU3257-001, 420 mg, 0.64 mmol) in THF (7 ml) at 0° C. was added 1M TBAF in THF (1.27 ml). The reaction was allowed to warm to room temperature and stirred for 1 h. The reaction mixture was diluted with EtOAc (10 ml), washed with water (3×10 ml) and saturated aqueous sodium chloride (10 ml). The organic extract was dried over sodium sulphate, filtered and concentrated under vacuo. The crude material was purified by flash column chromatography (0-10% MeOH/EtOAc) to obtain 379 mg (98%) of cis-rac-tert-butyl (3R,4S)-3-hydroxy-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate EV-AU3260-001 as a colourless powder. LCMS (method D): retention time 1.18 min, M/z=545 (M+1).
-
- To a stirred solution of rac-tert-butyl (3R,4S)-3-hydroxy-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate (EV-AU3260-001, 379 mg, 0.7 mmol) in DCM (10 ml) at 0° C. was added Et3N (145 μl, 1.04 mmol) and MsCl (65 μl, 0.84 mmol). The reaction was allowed to reach room temperature while stirring for 2 h. The reaction mixture was washed with water (5 ml) and the organic layer was dried over sodium sulphate, filtered and concentrated under vacuum to obtain 410 mg (95%) of cis-rac-tert-butyl (3R,4S)-3-(methanesulfonyloxy)-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate EV-AU3262-001 as a colourless powder. LCMS (method D): retention time 1.24 min, M/z=623 (M+1).
-
- To a stirred solution of cis-rac-tert-butyl (3R,4S)-3-(methanesulfonyloxy)-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate (EV-AU3262-001, 410 mg, 0.66 mmol) in DMSO (2 ml) was added sodium azide (128 mg, 1.98 mmol) and the reaction was stirred at 90° C. for 14 h. The reaction was then cooled to room temperature and diluted with EtOAc (10 ml). The solution was washed with water (3×10 ml), saturated aqueous sodium chloride (2×10 ml) and the organic extract was dried over sodium sulphate, filtered and concentrated in vacuo. The crude was purified by flash column chromatography (eluting with 50-100% EtOAc/heptanes) to obtain 272 mg (72%) of trans-rac-tert-butyl (3R,4R)-3-azido-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate EV-AU3263-001 as a colourless powder. LCMS (method D): retention time 1.32 min, M/z=570 (M+1).
-
- A solution of trans-rac-tert-butyl (3R,4R)-3-azido-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate (EV-AU3263-001, 272 mg, 0.48 mmol) in EtOAc (8 ml) was stirred under a hydrogen atmosphere at room temperature for 12 h. The reaction mixture was filtered through a filter paper, the filter was washed with MeOH and the filtrate concentrated in vacuo to obtain 230 mg (80%) of trans-rac-tert-butyl (3R,4R)-3-amino-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate EV-AU3267-001 as an off white powder. LCMS (method D): retention time 1.07 min, M/z=544 (M+1).
-
- To a stirred solution of trans-rac-tert-butyl (3R,4R)-3-amino-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate (EV-AU3267-001, 70 mg, 0.13 mmol) and (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride (26 mg, 0.15 mmol) in DMF (1 ml) was added HATU (59 mg, 0.15 mmol) and DIPEA (49 μl, 0.28 mmol) and the reaction was stirred at room temperature for 2 h. The solvent was then removed under vacuum and the crude was purified by preparative HPLC (acidic method) to give 20 mg (24%) of trans-rac-tert-butyl (3R,4R)-3-[(2E)-4-(dimethylamino)but-2-enamido]-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate EV-AU3279-001 as an off white solid. LCMS (method D): retention time 1.14 min, M/z=655 (M+1).
-
- 2M HCl in diethyl ether (0.76 ml) was added to trans-rac-tert-butyl (3R,4R)-3-[(2E)-4-(dimethylamino)but-2-enamido]-4-{N-methyl2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}pyrrolidine-1-carboxylate (EV-AU3279-001, 20 mg, 0.03 mmol) and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated in vacuo to obtain 17 mg (78%) of rac-2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,4R)-4-[(2E)-4-(dimethylamino)but-2-enamido]pyrrolidin-3-yl]-N,1-dimethyl-1H-1,3-benzodiazole-5-carboxamide hydrochloride I-1 (EV-AU3282-001) as an off white solid. LCMS (method A): retention time 1.43 min, M/z=555 (M+1).
- Cis-rac-(2E)-N-[(3R,4S)-3-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-4-yl]-4-(dimethylamino)but-2-enamide EV-AU3261-001 (EOAI3449030, I-3) was synthesised according to the procedures described in Scheme 1.4, steps 1 to 10, using intermediate methyl 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylate EV-AR6658-001 synthesised as described in Scheme 1:
-
- To a solution of trans-rac-tert-butyl (3R,4R)-3-amino-4-hydroxypiperidine-1-carboxylate (250 mg, 1.16 mmol) in DCM (5 ml) at 0° C. was added triethylamine (484 μl, 3.47 mmol) and benzyl chloroformate (198 μl, 1.39 mmol). The reaction mixture was left to stir at 0° C. for 15 minutes. The solution was allowed to warm to room temperature and stirred for a further 12 h. The reaction was quenched with water (10 ml) and extracted with DCM (3×10 ml). The combined organic fractions were dried with sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by column chromatography (20-80% EtOAc/heptanes) to obtain 0.21 g (52%) of trans-rac-tert-butyl (3R,4R)-3-{[(benzyloxy)carbonyl]amino}-4-hydroxypiperidine-1-carboxylate EV-AU3233-001 as a colourless viscous oil. LCMS (method D): retention time 1.12 min, M/z=373 (M+Na).
-
- Trans-rac-tert-butyl (3R,4R)-3-{[(benzyloxy)carbonyl]amino}-4-hydroxypiperidine-1-carboxylate (EV-AU3233-001 and EV-AU3236-001 combined, 390 mg, 1.11 mmol) was dissolved in 4M HCl in dioxane (5.56 ml) and stirred at room temperature for 1 h. The solvent was removed under vacuum to obtain 0.27 g (86%) of trans-rac-benzyl N-[(3R,4R)-4-hydroxypiperidin-3-yl]carbamate hydrochloride EV-AU3238-001 as a white solid. LCMS (method D): retention time 0.64 min, M/z=251 (M+1).
-
- To a solution of methyl 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylate (EV-AR6658-001, 330 mg, 0.95 mmol) in DMF (5 ml) was added DIPEA (0.55 ml, 3.33 mmol) and HATU (435 mg, 1.14 mmol) and the reaction was stirred under nitrogen at room temperature for 1 h. Benzyl N-[(3R,4R)-4-hydroxypiperidin-3-yl]carbamate hydrochloride (273 mg, 0.95 mmol) was added and the reaction was stirred for a further 2 h at room temperature. The reaction was quenched with water (5 ml) and extracted with ethyl acetate (5 ml×3). The combined organic extracts were washed with water (5 ml) and saturated aqueous sodium chloride (2×5 ml), dried with sodium sulfate, filtered and concentrated under vacuum. The crude was purified by column chromatography (50-100% EtOAc/heptanes, followed by 0-20% MeOH/EtOAc) to obtain 0.48 g (70%) of trans-rac-benzyl N-[(3R,4R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-4-hydroxypiperidin-3-yl]carbamate EV-AU3240-001 as a colourless viscous oil. LCMS (method D): retention time 1.11 min, M/z=579 (M+1).
-
- A solution of trans-rac-benzyl N-[(3R,4R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-4-hydroxypiperidin-3-yl]carbamate (EV-AU3240-001, 480 mg, 0.83 mmol) in ethanol (10 ml) was stirred at room temperature for 12 h under a hydrogen atmosphere in the presence of Pd/C (5%, 176.55 mg, 0.08 mmol). The reaction was filtered through a Kieselguhr pad, the filter was washed with MeOH and concentrated under vacuum to obtain 0.38 g (90%) of trans-rac-(3R,4R)-3-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-4-ol EV-AU3242-001 as a white solid. LCMS (method D): retention time 0.90 min, M/z=445 (M+1).
-
- To a solution of trans-rac-(3R,4R)-3-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-4-ol (EV-AU3242-001, 87%, 380 mg, 0.74 mmol) in DCM (5 ml) was added triethylamine (114 μl, 0.82 mmol) and di-tert-butyl dicarbonate (178 mg, 0.82 mmol) and the reaction was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous sodium bicarbonate and extracted with DCM (10 ml). The aqueous layer was washed with DCM (10 ml) and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under vacuum to obtain 0.27 g (63%) of trans-rac-tert-butyl N-[(3R,4R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-4-hydroxypiperidin-3-yl]carbamate EV-AU3245-001 as a white solid. LCMS (method D): retention time 1.09 min, M/z=545 (M+1).
-
- To a solution of trans-rac-tert-butyl N-[(3R,4R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-4-hydroxypiperidin-3-yl]carbamate (EV-AU3245-001, 269 mg, 0.49 mmol) in DCM (8 ml) at 0° C. was added triethylamine (103 μl, 0.74 mmol) and mesyl chloride (46 μl, 0.59 mmol). The reaction was stirred and allowed to reach room temperature over 2 h. The reaction mixture was washed with water (5 ml) and the organic layer was dried over sodium sulfate, filtered and concentrated under vacuum to obtain 0.31 g (81%) of trans-rac-tert-butyl N-[(3R,4R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-4-(methanesulfonyloxy)piperidin-3-yl]carbamate EV-AU3251-001 as a colourless viscous oil. LCMS (method D): retention time 1.18 min, M/z=623 (M+1).
-
- To a solution of trans-rac-tert-butyl N-[(3R,4R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-4-(methanesulfonyloxy)piperidin-3-yl]carbamate (EV-AU3251-001, 313 mg, 0.5 mmol) in DMSO (1.5 ml) was added sodium azide (98 mg, 1.51 mmol) and the reaction was left to stir at 90° C. for 14 h. The reaction was cooled to room temperature and diluted with EtOAc (10 ml). The organic layer was washed with water (3×10 ml) and saturated aqueous sodium chloride (2×10 ml). The organic extract was dried over sodium sulfate, filtered and concentrated under vacuum. The crude was purified by column chromatography (50-100% EtOAc/heptanes) to obtain 0.12 g (43%) of cis-rac-tert-butyl N-[(3R,4S)-4-azido-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate EV-AU3252-001 as a white solid. LCMS (method D): retention time 1.25 min, M/z=570 (M+1).
-
- A solution of cis-rac-tert-butyl N-[(3R,4S)-4-azido-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AU3252-001, 125 mg, 0.22 mmol) in EtOAc (4 ml) was treated with Pd/C (5% w/w, 47 mg, 0.02 mmol) and stirred under one atmosphere of hydrogen for 12 h. The crude mixture was filtered through glass fibre filter paper, the filter was washed with MeOH and the filtrate concentrated to obtain 0.10 g (85%) of cis-rac-tert-butyl N-[(3R,4S)-4-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate EV-AU3256-001 as an off white solid. LCMS (method D): retention time 0.98 min, M/z=544 (M+1).
-
- To a solution of (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride (18 mg, 0.11 mmol) and cis-rac-tert-butyl N-[(3R,4S)-4-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AU3256-001, 50 mg, 0.09 mmol) in DMF (1 ml) were added HATU (42 mg, 0.11 mmol) and DIPEA (35 μl, 0.2 mmol) and the reaction was stirred at room temperature for 2 h. The solvent was removed under vacuum and the crude purified by preparative HPLC (acidic method) to obtain 25 mg (37%) of cis-rac-tert-butyl N-[(3R,4S)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-4-[(2E)-4-(dimethylamino)but-2-enamido]piperidin-3-yl]carbamate EV-AU3258-001 as an off white solid. LCMS (method D): retention time 2.12 min, M/z=655 (M+1).
-
- Cis-rac-tert-butyl N-[(3R,4S)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-4-[(2E)-4-(dimethylamino)but-2-enamido]piperidin-3-yl]carbamate (EV-AU3258-001, 25 mg, 0.04 mmol) was dissolved in 2M HCl in diethyl ether (1.93 ml) and left to stir at room temperature for 2 h. The solvent was removed under vacuum to obtain 18 mg (75%) of cis-rac-(2E)-N-[(3R,4S)-3-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-4-yl]-4-(dimethylamino)but-2-enamide I-3 (EV-AU3261-001) as an off white solid. LCMS (method A): retention time 1.48 min, M/z=555 (M+1).
- Cis-rac-2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,5S)-5-[(2E)-4-(dimethylamino)but-2-enamido]piperidin-3-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxamide EV-AE3994-001 (EOAI3447033, I-8) was synthesised according to the procedures described in Scheme 1.5, steps 1 to 3, from 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid EV-AR6658-001 synthesised as described in Scheme 1:
-
- To a solution of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid (EV-AR6658-001, prepared as in Scheme 1, 100 mg, 0.14 mmol) in DMF (1 ml) was added DIPEA (167 μl, 1.01 mmol) and HATU (132 mg, 0.35 mmol) and the reaction was left to stir under nitrogen at room temperature for 20 minutes. Cis-rac-tert-butyl (3R,5S)-3,5-diaminopiperidine-1-carboxylate (EV-AU3202-001 prepared as described in J. Org. Chem., 2013, 78(23), p 12236-12242), 155 mg, 0.72 mmol) in DMF (1 ml) was added and the reaction was stirred for a further 2 h at room temperature. The reaction was quenched with water (5 ml) and extracted with ethyl acetate (5 ml×3). The combined organic extracts were washed with saturated aqueous sodium chloride (5 ml), dried over sodium sulfate, filtered and concentrated under vacuum. The crude was purified by preparative HPLC (acidic method) to obtain 22 mg (14%) of cis-rac-tert-butyl (3R,5S)-3-amino-5-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}piperidine-1-carboxylate EV-AE3991-001 as a white solid. LCMS (method D): retention time 1.00 min, M/z=544 (M+1).
-
- A solution of cis-rac-tert-butyl (3R,5S)-3-amino-5-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}piperidine-1-carboxylate (EV-AE3991-001, 22 mg, 0.04 mmol), (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride (8 mg, 0.049 mmol) and HATU (18 mg, 0.049 mmol) in dry DMF (0.5 ml) was treated with DIPEA (16 μl, 0.089 mmol) at room temperature. The mixture was stirred for 20 minutes at room temperature. The reaction mixture was diluted with EtOAc (5 ml) and washed with water (2 ml). The aqueous layer was re-extracted with EtOAc (5 ml). The EtOAc layers were combined, washed with saturated aqueous sodium chloride (5 ml), dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by preparative HPLC (acidic method) to obtain 6 mg (22%) of cis-rac-tert-butyl (3R,5S)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-5-[(2E)-4-(dimethylamino)but-2-enamido]piperidine-1-carboxylate EV-AE3993-001 as a colourless crystalline solid. LCMS (method D): retention time 1.03 min, M/z=655 (M+1).
-
- To cis-rac-tert-butyl (3R,5S)-3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-amido}-5-[(2E)-4-(dimethylamino)but-2-enamido]piperidine-1-carboxylate (EV-AE3993-001, 6 mg, 0.009 mmol) was added 2M HCl in ether (0.05 ml, 0.092 mmol). The suspension mixture was allowed to stand at room temperature for 1 h. Another portion of 2M HCl in ether (0.05 ml) was added, the reaction mixture was stirred briefly then allowed to stand for 30 mins. The reaction mixture was concentrated to dryness to obtain 5 mg (92%) of rac-2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-N-[(3R,5S)-5-[(2E)-4-(dimethylamino)but-2-enamido]piperidin-3-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxamide dihydrochloride I-8 (EV-AE3994-001) as a white powder. LCMS (method C): retention time 2.90 min, M/z=555 (M+1).
- Cis-rac-(2E)-N-[(3R,5S)-5-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]-4-(dimethylamino)but-2-enamide EV-AU3215-001 (EOAI3442261, 1-10) was synthesised according to the procedures described in Scheme 1.6, steps 1 to 5, from 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid (synthesised as described in Scheme 1).
-
- To a solution of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid (EV-AT0481-001, 410 mg, 1.18 mmol) in DMF (8 ml) was added DIPEA (235 μl, 1.42 mmol) and HATU (540 mg, 1.42 mmol) and the reaction was stirred under nitrogen at room temperature for 1 h. 6,7-Dibenzyl 3,6,7-triazabicyclo[3.2.1]octane-6,7-dicarboxylate (EV-AT0491-001 prepared as described in J. Org. Chem., 2013, 78(23), p 12236-12242, 497 mg, 1.3 mmol) in DMF (2 ml) was added and the reaction was stirred for a further 2 h. The mixture was quenched with saturated aqueous ammonium chloride (5 ml) and extracted with ethyl acetate (5 ml×3). The combined organic extracts were washed with water (5 ml), saturated aqueous sodium chloride (5 ml), dried over sodium sulfate, filtered and concentrated under vacuum. The crude product was purified via column chromatography (80:100 EtOAc/heptanes, then 0:5% MeOH/EtOAc) to obtain 0.82 g (96%) of 6,7-dibenzyl 3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-3,6,7-triazabicyclo[3.2.1]octane-6,7-dicarboxylate EV-AT0494-001 as an orange solid. LCMS (method D): retention time 1.28 min, M/z=710 (M+1).
-
- A 0.05M solution of 6,7-dibenzyl 3-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-3,6,7-triazabicyclo[3.2.1]octane-6,7-dicarboxylate (EV-AT0494-001, 22 ml) in EtOH was subjected to H-Cube conditions (1 ml/min, 1 bar, 80° C., full hydrogen mode) over a Pd/C (10%) catalyst cartridge. The solvent was removed under vacuum to obtain 0.41 g (82%) of cis-rac-(3R,5S)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidine-3,5-diamine EV-AT0497-001 as an orange oil. LCMS (method D): retention time 0.76 min, M/z=444 (M+1).
-
- To a solution of cis-rac-(3R,5S)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidine-3,5-diamine (EV-AT0497-001, 415 mg, 0.94 mmol) in DCM (7.5 ml) was added triethylamine (144 μl, 1.03 mmol) and di-tert-butyl dicarbonate (184 mg, 0.84 mmol) and the reaction was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous sodium bicarbonate (10 ml) and extracted with DCM (10 ml). The aqueous layer was washed with DCM (10 ml), the combined organic extracts were dried over sodium sulfate, filtered and concentrated under vacuum. The crude was purified by reverse phase column chromatography (10-90% MeCN in water, with both solvents containing 0.1% formic acid) to obtain 0.17 g (30%) of formic acid; cis-tert-butyl N-(5-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl)carbamate EV-AT0498-001 as an off-white solid. LCMS (method A): retention time 2.17 min, M/z=544 (M+1).
-
- To a solution of (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride (20 mg, 0.12 mmol) in DMF (0.5 ml) was added HATU (55 mg, 0.14 mmol) and DIPEA (60 μl, 0.36 mmol) and the solution was stirred at room temperature for 1 h. Formic acid; cis-tert-butyl N-(5-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl)carbamate (EV-AT0498-001, 52.52 mg, 0.1 mmol) in DMF (0.5 ml) was added and the reaction was stirred for a further 3 h. The solvent was removed under vacuum and the crude was purified by preparative HPLC (acidic method) to obtain 14 mg (18%) of formic acid; cis-tert-butyl N-(5-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl)carbamate EV-AU3206-001 as a white solid. LCMS (method A): retention time 2.24 min, M/z=655 (M+1).
-
- Formic acid; cis-tert-butyl N-(5-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl)carbamate (EV-AU3206-001, 14 mg, 0.02 mmol) was dissolved in 2M HCl in diethyl ether (1.08 ml) and stirred at room temperature for 2 h. The reaction mixture was concentrated under vacuum to obtain 19 mg (91%) of cis-rac-(2E)-N-[(3R,5S)-5-amino-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]-4-(dimethylamino)but-2-enamide I-10, (EV-AU3215-001) as an off white solid. LCMS (method A): retention time 1.33 min, M/z=555 (M+1).
- (2E)-N-[2-(1-{2-[1-(Cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-[2-(1H-imidazol-5-yl)ethyl]formamido)ethyl]-4-(dimethylamino)but-2-enamide EV-AE3995-001 (EOAI3447034, I-7) was synthesised according to the procedures described in Scheme 1.7, steps 1 to 4, from 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid EV-AR3168-002 synthesised as described in Scheme 1:
-
- To a stirred solution of tert-butyl N-(2-oxoethyl)carbamate (CAS 89711-08-0, 649 mg, 4.07 mmol) and 2-(1H-imidazol-5-yl)ethan-1-amine dihydrochloride (CAS 56-92-8, 500 mg, 2.72 mmol) in MeOH (15 ml) was added acetic acid (0.16 ml, 2.72 mmol) followed by portion wise addition of sodium triacetoxyborohydride (2.0 g, 9.42 mmol). The reaction was stirred at room temperature for 16 h. The solvent was removed in vacuo and the residue was purified by reverse phase flash column chromatography (10-100% in MeCN/water, both solvents containing 0.1% NH3) to obtain 80 mg (9%) of tert-butyl N-(2-{[2-(1H-imidazol-5-yl)ethyl]amino}ethyl)carbamate EV-AU3211-001 as a yellow oil. LCMS (method J): retention time 1.28 min, M/z=255 (M+1).
-
- To a stirred solution of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid (EV-AR3168-002, 109 mg, 0.31 mmol) in DMF (2 ml) was added HATU (132 mg, 0.35 mmol) and DIPEA (110 μl, 0.63 mmol) and the reaction was stirred at room temperature for 2 h. The reaction mixture was submitted directly for preparative HPLC (basic method) to obtain 25 mg (14%) of tert-butyl N-[2-(1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-[2-(1H-imidazol-5-yl)ethyl]formamido)ethyl]carbamate EV-AU3217-001 as a colourless powder. LCMS (method D): retention time 0.99 min, M/Z=583 (M+1).
-
- 2M HCl in ether (0.22 ml, 0.43 mmol) was added to tert-butyl N-[2-(1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-[2-(1H-imidazol-5-yl)ethyl]formamido)ethyl]carbamate (EV-AU3217-001, 25 mg, 0.043 mmol) and the resulting mixture was stirred at room temperature for 2 h. The solvent was removed in vacuo and the residue azeotroped with DCM (2 ml). The resulting solid was dried to afford 27 mg (quantitative) of N-(2-aminoethyl)-2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-1-methyl-1H-1,3-benzodiazole-5-carboxamide dihydrochloride EV-AE3992-001 as a white powder. LCMS (method D): retention time 0.78 min, M/z=483 (M+1).
-
- To a stirred solution of N-(2-aminoethyl)-2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-1-methyl-1H-1,3-benzodiazole-5-carboxamide dihydrochloride (EV-AE3992-001, 27 mg, 0.049 mmol), HATU (22 mg, 0.058 mmol) and (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride (10 mg, 0.058 mmol) in dry DMF (1 ml) was added DIPEA (30 μl, 0.17 mmol). The reaction was stirred at room temperature for 20 minutes. The solvent was removed in vacuo and the residue was submitted for preparative HPLC (acidic method) to afford 2.6 mg (8%) of (2E)-N-[2-(1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-[2-(1H-imidazol-5-yl)ethyl]formamido)ethyl]-4-(dimethylamino)but-2-enamide formate EV-AE3995-001 as a colourless solid. LCMS (method C): retention time 2.72 min, M/z=594 (M+1).
- (2E)-N-[(3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]-4-(dimethylamino)but-2-enamide EV-AQ1925-001 (EOAI3426752, 1-12) was synthesised according to the procedures described in Scheme 1.8, steps 1 to 3, from 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid EV-AR3168-002 synthesised as described in Scheme 1:
-
- To a stirred solution of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid (EV-AR3168-002, 300 mg, 0.87 mmol) and HATU (362 mg, 0.95 mmol) in dry DMF (9 ml) was added DIPEA (166 μl, 0.95 mmol). The reaction was stirred for 1 h at room temperature and tert-butyl N-[(3R)-piperidin-3-yl]carbamate (CAS 309956-78-3, 208 mg, 1.04 mmol) was added. The reaction was stirred at room temperature for 16 h and concentrated in vacuo. The residue was partitioned between DCM (30 ml) and saturated aqueous sodium bicarbonate (30 ml). The aqueous layer was extracted with DCM (20 ml) and the combined organics were washed with water (20 ml) and saturated aqueous sodium chloride (20 ml), dried over magnesium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash column chromatography (1-10% MeOH/DCM) to obtain 352 mg (76%) of tert-butyl N-[(3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate EV-AP0493-002 as a yellow crystalline solid. LCMS (method D): retention time 1.34 min, M/z=529 (M+1).
-
- To a stirred solution of tert-butyl N-[(3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]carbamate (EV-AP0493-002, 352 mg, 0.66 mmol) in methanol (3 ml) was added 4M HCl in dioxane (7 ml). The reaction was stirred at room temperature for 3 h. The reaction mixture was concentrated in vacuo and the resulting solid was dried to obtain 299 mg (96%) of (3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-amine hydrochloride EV-AP4097-001 as a yellow powder. LCMS (method D): retention time 1.00 min, M/z=429 (M+1).
-
- To a stirred solution of (3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-amine hydrochloride (EV-AP4097-001, 50 mg, 0.11 mmol) in DMF (1 ml) was added (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride (21 mg, 0.13 mmol), DIPEA (62 mg, 0.54 mmol) and TBTU (45 mg, 0.14 mmol). The mixture was stirred at room temperature for 2 h. The reaction mixture was filtered and the filtrate was submitted for preparative HPLC (basic method) to afford 25 mg (43%) of (2E)-N-[(3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]-4-(dimethylamino)but-2-enamide I-12 (EV-AQ1925-001) as a white solid. LCMS (method A): retention time 1.88 min, M/z=540 (M+1).
- N-[(3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]prop-2-enamide EV-AO7886-002 (EOAI3426521, 1-13) was synthesised according to the procedures described in Scheme 1.9 from 3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-amine hydrochloride EV-AP4097-001 synthesised as described in Scheme 1.8:
- To a stirred solution of DIPEA (178 μl, 1.02 mmol), DMAP (1.2 mg, 0.01 mmol) and (3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-amine hydrochloride (EV-AP4097-001, 50 mg, 0.11 mmol) in DCM (5 ml) at 0° C. was added a solution of prop-2-enoyl chloride (26 μl, 0.32 mmol) in DCM (3 ml) dropwise. The reaction was stirred at 0° C. for 1 h. Water (1 ml) was added and the layers were separated using a hydrophobic filter. The organic phase was concentrated in vacuo and the crude material purified by preparative HPLC (acidic method) to afford 21 mg (41%) of N-[(3R)-1-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-1H-1,3-benzodiazole-5-carbonyl}piperidin-3-yl]prop-2-enamide I-13 (EV-AO7886-002) as a colourless crystalline solid. LCMS (method A): retention time 2.61 min, M/z=483 (M+1).
- The following compounds were synthesised according to procedures described above:
-
Salt LCMS LCMS Stoichi- Structure # Mol Wt Tret M/z (+) Method Salt ometry I-1 554.686 1.43 min 555.3 A HCl 2 I-2 569.697 1.98 min 571.2 A HCl 2 I-3 554.686 1.48 min 555.3 A HCl 2 I-4 540.659 1.44 min 541.3 A HCl 2 I-5 540.659 1.43 min 541.3 A HCl 2 I-6 497.591 3.35 min 498.2 C HCl 1 I-7 593.722 2.72 min 594.3 C HCO2H 1 I-8 554.686 2.90 min 555.2 C HCl 2 I-9 540.659 2.80 min 541.2 C HCl 2 I-10 554.686 1.33 min 555.2 A HCl 2 I-11 484.550 1.96 min 485.1 A HCl 1 I-12 539.671 1.88 min 540.3 A I-13 482.577 2.61 min 483.3 A - N-[(1S,4R,6R,7R)-7-amino-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-6-yl]-N-methylprop-2-enamide 1-16 (EV-AZ4416-001) (EOAI3478697) LCMS (method A): retention time 1.93 min, M/z=554.4 (M+1) and N-[(1S,4R,6S,7R)-7-amino-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-6-yl]-N-methylprop-2-enamide 1-17 (EV-AZ4417-001) (EOAI3478698) LCMS (method A): retention time 2.10 min, M/z=554.4 (M+1) were synthesised according to procedures described in Scheme 1.10, steps 1-10, from 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid EV-AV3032-001 which was synthesised according to the procedures described in Scheme 1.
- A solution of (4R,6R)-3-bromo-1-[(1S)-1-phenylethyl]-1-azatricyclo[2.2.1.0]heptan-1-ium bromide (EV-AW8588-001, 8.70 g, 19.4 mmol) (synthesised as in Adv. Synth. Catal. 2005, 347, 1242-1246) in acetonitrile: water (1:1, 100 ml) was stirred at 65° C. for 20 h. The reaction mixture was concentrated in vacuo and the residue was purified by flash column chromatography (20-80% EtOAc/heptane) to afford 4.29 g (73%) of (1R,4R,6S,7R)-7-bromo-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-6-ol EV-AY4949-001 as an off-white solid. 1H NMR (250 MHz, Chloroform-d) δ 7.38-7.14 (m, 5H), 4.10 (s, 2H), 3.58 (q, J=6.1 Hz, 1H), 3.36-3.23 (m, 1H), 2.65 (dt, J=9.0, 3.1 Hz, 1H), 2.58-2.46 (m, 1H), 2.28-1.91 (m, 4H), 1.32 (d, J=6.4 Hz, 3H). No LCMS data.
- (1R,4R,6S,7R)-7-bromo-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-6-ol (EV-AY4949-001, 4.29 g, 14.2 mmol) was dissolved in 7N ammonia in methanol (15 ml) and the resulting mixture was heated at 65° C. for 2 h. The solvent was removed in vacuo to afford 4.62 g (quantitative) of (1S,4R,6S,7R)-7-amino-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-6-ol hydrobromide EV-AY4952-001 as a yellow solid. LCMS (method D): retention time 0.20 min, M/z=233 (M+1).
- Di-tert-butyl dicarbonate (3.41 g, 15.6 mmol) was added to a solution of (1R,4R,6S,7R)-7-amino-2-[(1 S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-6-ol hydrobromide (EV-AY4952-001, 4.62 g, 14.2 mmol) and triethylamine (2.97 ml, 21.28 mmol) in DCM (50 ml). The resulting mixture was stirred at room temperature for 2.5 h, washed with saturated aqueous sodium bicarbonate (35 ml), water (2×30 ml) and saturated aqueous sodium chloride (35 ml), dried over sodium sulfate and concentrated in vacuo. The resulting solid was triturated with DCM: diethyl ether (1:4, 20 ml), filtered and dried to obtain 3.24 g (65%) of tert-butyl N-[(1S,4R,6S,7R)-6-hydroxy-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AY4953-001 as an off-white solid. LCMS (method D): retention time 1.02 min, M/z=333 (M+1).
- A solution of tert-butyl N-[(1S,4R,6S,7R)-6-hydroxy-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY4953-001, 350 mg, 1.05 mmol) in ethanol (10 ml) was purged with nitrogen. Pd/C (5%, 224 mg, 0.11 mmol) was added, the reaction mixture was purged with nitrogen and stirred under a hydrogen atmosphere for 12 h. The reaction mixture was filtered through filter paper (washing with methanol). The filtrate was concentrated in vacuo to afford 170 mg (71%) of tert-butyl N-[(1S,4R,6S,7R)-6-hydroxy-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AW5569-001 as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 5.84 (s, 1H), 3.99 (d, J=40.5 Hz, 2H), 3.12 (s, 1H), 2.98 (d, J=9.2 Hz, 1H), 2.53-2.41 (m, 2H), 1.98 (dd, J=13.7, 6.9 Hz, 1H), 1.75 (d, J=13.1 Hz, 1H), 1.44 (s, 9H). No LCMS data.
- To a solution of 2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carboxylic acid (EV-AV3032-001, 0.969 g, 2.58 mmol) in DMF (12 ml) was added HATU (1.08 g, 2.83 mmol) and DIPEA (1.12 ml, 6.44 mmol) followed by tert-butyl N-[(1S,4R,6S,7R)-6-hydroxy-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AW5569-001, 98%, 0.60 g, 2.58 mmol). The resulting mixture was stirred at room temperature for 30 minutes. The reaction was diluted with EtOAc (100 ml) and water (100 ml). The organic phase was collected and the aqueous phase was extracted with EtOAc (100 ml). The combined organics were washed with saturated aqueous sodium chloride (100 ml), dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by flash column chromatography (50-100% EtOAc/heptane then 5% methanol/EtOAc) to afford 736 mg (48%) of tert-butyl N-[(1S,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-hydroxy-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AY5029-001 as an off-white solid. LCMS (method D) retention time 1.19 min, M/z=587 (M+1).
- To a solution of tert-butyl N-[(1S,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-hydroxy-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY5029-001, 490 mg, 0.84 mmol) in DCM (10 ml) at 0° C. was added Dess-Martin periodinane (710 mg, 1.67 mmol) and the reaction was allowed to warm to room temperature. The reaction mixture was stirred for 24 h, quenched with saturated aqueous sodium thiosulfate (10 ml) and extracted with DCM (3×20 ml). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo. The remaining residue was purified by preparative HPLC (acidic method) to afford 471 mg (89%) of tert-butyl N-[(1S,4R,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-oxo-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AZ4415-001 as a white solid. LCMS (method D): retention time 1.25 min, M/z=585 (M+1).
- A solution of tert-butyl N-[(1S,4R,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-oxo-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AZ4415-001, 86%, 109 mg, 0.16 mmol) in DCE (1.5 ml) at room temperature was stirred with activated 3 A molecular sieves. N-methyl-1-phenylmethanamine (41 μl, 0.32 mmol), sodium triacetoxyborohydride (STAB, 51 mg, 0.24 mmol) and acetic acid (10 μl, 0.17 mmol) were added and the reaction was stirred at room temperature for 72 h. The reaction mixture was filtered and the molecular sieves were washed with DCM (20 ml). The DCM solution was washed with saturated aqueous sodium bicarbonate (15 ml) and the aqueous was re-extracted with DCM (3×15 ml). The combined organics were washed with saturated aqueous sodium chloride (15 ml), dried over magnesium sulfate and concentrated in vacuo. The crude material was dissolved in methanol (5 ml) and loaded on to a 2 g SCX-II cartridge. The cartridge was flushed through with methanol and 2.8 M ammonia in methanol. The relevant fractions were concentrated in vacuo to obtain 71 mg (52%) of tert-butyl N-[(1S,4R,7R)-6-[benzyl(methyl)amino]-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AZ4411-003 as a colourless oil. LCMS (method H): retention time 4.43 min and 4.83 min, M/z=690 (M+1).
- A solution of 0.05M tert-butyl N-[(1S,4R,6S,7R)-6-[benzyl(methyl)amino]-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AZ4411-003, 81%, 71 mg, 0.08 mmol) in methanol (2.1 ml) was subjected to H-Cube conditions (1 ml/min, 60 bar, 60° C., 2 passes) over a Pearlman's catalyst (20% Pd(OH)2/C) cartridge. The resulting solution was concentrated in vacuo to obtain 45 mg (60%) of tert-butyl N-[(1R,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(methylamino)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AZ4413-002 as a yellow oil. LCMS (method D): retention time 1.08 min, M/z=600 (M+1).
- To a solution of tert-butyl N-[(1R,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(methylamino)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AZ4413-002, 67%, 45 mg, 0.05 mmol) in dioxane (0.5 ml) was added triethylamine (14 μl, 0.1 mmol) followed by prop-2-enoyl chloride (9 μl, 0.11 mmol). The reaction mixture was stirred at room temperature for 50 minutes. Additional prop-2-enoyl chloride (5 ul) was added to the reaction and stirring was continued for an additional 1.5 h. The resulting reaction mixture was concentrated in vacuo and purified by preparative HPLC (acidic method) to obtain 14 mg (37%) of tert-butyl N-[(1S,4R,6R,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(N-methylprop-2-enamido)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AZ4414-002 (chirality arbitrarily assigned) as a white solid. LCMS (method A): retention time 3.19 min, M/z=654 (M+1). 4.4 mg (12%) of tert-butyl N-[(1S,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(N-methylprop-2-enamido)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AZ4414-003 (chirality arbitrarily assigned) were also isolated as a white solid. LCMS (method A): retention time 3.29 min, M/z=654 (M+1).
- To a stirred solution of tert-butyl N-[(1S,4R,6R,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(N-methylprop-2-enamido)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AZ4414-002, 14 mg, 0.02 mmol) in DCM (0.5 ml) was added TFA (20 μl, 0.26 mmol). The reaction was stirred at room temperature for 0.5 h. Additional TFA (80 μl, 1.04 mmol) was added and the reaction was continued for 1 h. The reaction mixture was concentrated in vacuo, re-dissolved in water and dried by lyophilization to afford 12 mg (78%) of N-[(1S,4R,6R,7R)-7-amino-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-6-yl]-N-methylprop-2-enamide; trifluoroacetic acid 1-16 (EV-AZ4416-001) (EOAI3478697) as a white solid. LCMS (method H): retention time 1.93 min, M/z=554 (M+1).
- To a stirred solution of tert-butyl N-[(1S,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(N-methylprop-2-enamido)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AZ4414-003, 92%, 4.4 mg, 0.01 mmol) in DCM (0.4 ml) was added TFA (29 μl, 0.38 mmol). The reaction was stirred at room temperature for 2 h. Additional TFA (20 μl, 0.26 mmol) was added and the reaction was continued for 30 minutes. The reaction mixture was concentrated in vacuo, re-dissolved in water and dried by lyophilization to afford 5 mg (quantitative) of N-[(1S,4R,6S,7R)-7-amino-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-6-yl]-N-methylprop-2-enamide; trifluoroacetic acid 1-17 (EV-AZ4417-001) (EOAI3478698) as a sticky white solid. LCMS (method A): retention time 2.10 min, M/z=554 (M+1).
- (1S,4R,6S,7R)-7-amino-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-6-yl prop-2-enoate I-15 (EV-AY5035-001) (EOAI3470264) LCMS (method A): retention time 2.23 min, M/z=541.3 (M+1) was synthesised according to the procedures described in Scheme 1 via synthesis of (1S,4R,6S,7R)-7-{[(tert-butoxy)carbonyl]amino}-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-6-yl prop-2-enoate EV-AY5034-002 described in Scheme 1.10, step 11.
- To a cold solution (0° C.) of tert-butyl N-[(1S,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-hydroxy-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY5029-001, 120 mg, 0.20 mmol) in DCM (2 ml) was added triethylamine (70 μl, 0.51 mmol) followed by prop-2-enoyl chloride (20 μl, 0.25 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 1 h. Triethylamine (70 μl, 0.51 mmol) was added followed by prop-2-enoyl chloride (40 μl, 0.50 mmol). The mixture was stirred at room temperature for 30 minutes. The reaction was quenched using saturated aqueous ammonium chloride (25 ml) and extracted using DCM (3×25 ml). The organic extracts were combined, dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by flash column chromatography (20-100% EtOAc/heptane) and by preparative HPLC (acidic method) to obtain 6 mg (18%) of (1S,4R,6S,7R)-7-{[(tert-butoxy)carbonyl]amino}-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-6-yl prop-2-enoate EV-AY5034-002 as a white powder. LCMS (method D): retention time 1.25 min, M/z=641 (M+1).
- N-[(1S,4R,6S,7R)-7-amino-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-6-yl]prop-2-enamide 1-14 (EV-AY4929-001) (EOAI3470263) LCMS (method A): retention time 2.07 min, M/z=540.3 (M+1) was synthesised according to procedures described in Scheme 1 via synthesis of tert-butyl N-[(1R,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(prop-2-enamido)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AW8586-002 described in Scheme 1.10, steps 12-14.
- DIAD (107 μl, 0.51 mmol) was added to a stirred solution of triphenylphosphane (134 mg, 0.51 mmol) in anhydrous THF (5 ml) under an atmosphere of nitrogen at 0° C. The reaction was stirred at 0° C. for 5 minutes then a solution of tert-butyl N-[(1S,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-hydroxy-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AY5029-001, 200 mg, 0.34 mmol) in anhydrous THF (5 ml) was added followed by 1H-isoindole-1,3(2H)-dione (41 μl, 0.34 mmol). The reaction mixture was stirred at room temperature for 18 h, concentrated in vacuo and purified by flash column chromatography (0-100% EtOAc/heptane) to obtain 138 mg (48%) of tert-butyl N-[(1S,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AW8584-001 as a white foam. LCMS (method D): retention time 1.28 min, M/z=716 (M+1).
- To a solution of tert-butyl N-[(1S,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AW8584-001, 134 mg, 0.19 mmol) in DCM (3 ml) was added hydrazine hydrate (1:1) (27 μl, 0.56 mmol). The reaction mixture was stirred at room temperature for 45 minutes and at 50° C. for 18 h, filtered and the filtrate was concentrated in vacuo. EtOAc (10 ml) was added to the residue and the mixture was stirred for 5 minutes then filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography (20-100% EtOAc/heptane) to obtain 75 mg (63%) of tert-butyl N-[(1R,4R,6S,7R)-6-amino-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AW8585-005 as a white foam. LCMS (method D): retention time 1.05 min, M/z=586 (M+1).
- To a solution of tert-butyl N-[(1R,4R,6S,7R)-6-amino-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (EV-AW8585-005, 92%, 75 mg, 0.12 mmol) in dioxane (2 ml) was added triethylamine (18 μl, 0.13 mmol) followed by prop-2-enoyl chloride (10 μl, 0.13 mmol). The reaction mixture was stirred at room temperature for 30 minutes, concentrated in vacuo and the resulting residue was purified by preparative HPLC (acidic method) to obtain 44 mg (59%) of tert-butyl N-[(1R,4R,6S,7R)-2-{2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-6-(prop-2-enamido)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate EV-AW8586-002 as a white solid. LCMS (method A): retention time 3.13 min, M/z=640 (M+1).
- Compounds of the present invention were assayed as inhibitors of PAD4 using the assay protocol described below.
- Compounds were solubilized in 100% DMSO to achieve 100 mM final compound concentration. Compound stock solutions were stored at RT. A series of dilutions were prepared in DMSO and mixed 8 times with 20 μL mixing volume. Final assay conditions were as follows:
-
- Reaction volume: 20 μl
- Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2
- Final concentrations:
- 100 nM hPAD4 enzyme
- 50 μM (8-fold sub-Km) substrate peptide
- 0.5% DMSO
- Total incubation time: 65 mins at 37° C.
- Stop solution: 40 μl 5% TCA in ACN
0.25 μL of compound solution was added to 10 μL of 200 nM PAD4 in assay buffer (100 mM Tris-HCl pH 7.6, 2 mM DTT). After 5 mins, 10 μL of 100 μM of substrate in buffer (100 mM Tris-HCl pH 7.6, 2 mM DTT, 2 mM CaCl2) was added and the reaction incubated for 60 mins at 37° C. The enzymatic reaction was quenched by addition of 40 μl of 5% TCA in ACN (1.7% TCA final concentration) stop solution. Arginine containing substrate and citrulline containing product (+1 Da mass shift) were subjected to solid phase extraction on Agilent RapidFire (RF) 300 system and detected on a coupled, triple quadrupole Agilent 6460 QQQ mass spectrometry (MS) device under application of multiple reaction monitoring (MRM) for quantitation.
- Table 2, below, shows the activity of selected compounds of this invention in the PAD4 assays described above. The compound numbers correspond to the compound numbers in Table 1. Compounds having an activity designated as “A” provided an IC50 of 0.1-1 μM; compounds having an activity designated as “B” provided an IC50 of 1-5 μM; compounds having an activity designated as “C” provided an IC50 of 5-10 μM; and compounds having an activity designated as “D” provided an IC50 of >10 μM. The term pIC50=−log(IC50). Compounds having an activity designated as “E” provided a pIC50 of 1-4; compounds having an activity designated as “F” provided a pIC50 of 4-5; and compounds having an activity designated as “G” provided a pIC50 of >5. “NA” stands for “not assayed.”
- Mass spectrometry was used to analyze covalent modification of protein by selected inhibitors. Recombinant human PAD4 was used at 4 mg/ml in 20 mM Tris pH7.6, 400 mM NaCl, 5 mM TCEP. Where applicable, buffer was supplemented with 5 mM CaCl2) to determine Calcium sensitivity of modification. Inhibitors were dissolved in DMSO at final concentrations of 0.2 mM to 5 mM and incubated with protein at 27° C. for 16 hours prior to analysis. Control experiments were performed with protein and DMSO in absence of inhibitor. Samples were centrifuged for 15 seconds at 10000 rpm at room temperature immediately prior to analysis using a Waters LCT-Premier TOF mass spectrometer, using a mobile phase from 5% to 80% acetonitrile in water supplemented by 0.1% formic acid.
- Covalent binding of an active compound to the target enzyme leads to time dependent loss of the enzyme activity. The rate of inactivation depends on the inhibitor concentration ([I]) and can be quantified under pseudo-first order conditions ([I]>>[hPAD4]).
- Inactivation kinetics experiments were performed in 384-well polystyrene plates at 37° C. Compounds (10-200 μM) and hPAD4 (4 μM) solutions were pre-incubated in assay buffer (100 mM Tris-HCl, pH 7.6) containing 10 mM CaCl2 and 2 mM DTT for 10 minutes to reach a temperature of 37° C. Equal volumes (10 μl) of compound and hPAD4 solutions were mixed at various time points between 0 and 70 minutes. At 70 minutes time point, the inactivation solution was diluted 10-fold in enzymatic reaction buffer (100 mM Tris-HCl, pH 7.6) containing 166.7 μM peptide substrate (H-TSTGGRQGSHH-CONH2), 1.1 mM CaCl2 and 2 mM DTT. After 30 minutes of incubation at 37° C. the enzymatic reaction was quenched by 3-fold dilution in 5% TCA solution in ACN. Substrate peptide arginine citrullination was determined by solid phase extraction mass spectrometry (SPE-MS). An Agilent RapidFire 300 equipped with a HILIC (H1) cartridge was used for sampling with solvents 0.1% TFA in H2O/ACN (20/80) for P1 and 0.1% TFA in H2O/ACN (50/50) for P2 and P3. Substrate and product peptide were detected using a coupled Agilent 6460 QQQ and multiple reaction monitoring (MRM) on transitions 562.3/969.4 and 562.8/541, respectively, in positive ion mode. DMSO content of the inactivation reaction was 1%. Cl-amidine (100 mM, final concentration during enzyme inactivation reaction) and 1% DMSO were used as positive and negative controls of the inactivation reaction, respectively.
- Pseudo-first order rate constants of inactivation reaction, kobs, were determined by fitting the time dependent loss of residual hPAD4 activity, Ares, with equation: Ares (t)=e−kobs*t. A plot of the pseudo-first order rate constants versus molar concentrations of the inhibitors allowed determination of the kinetic reaction constants: kinact—maximum rate of inactivation at infinite [I]; KI—inhibitor concentration, at which rate of inactivation is equal to ½kinact; kinact/KI.
- Certain compounds of the present invention were assayed according to the procedures described above and were found to covalently modify PAD4.
- Table 3, below, shows the activity of selected compounds of this invention in the covalent modification assay described above. The compound numbers correspond to the compound numbers in Table 1.
-
TABLE 2 PAD4 Activity hPAD4 hPAD4 mPAD4 mPAD4 RFMS RFMS RFMS RFMS Compound # IC50 μM pIC50 IC50 μM pIC50 I-1 B G B G I-2 A G A G I-3 D E D F I-4 D F D F I-5 B G A G I-6 D E NA NA I-7 D E NA NA I-8 C G C F I-9 B G A G I-10 D F D F I-11 D F NA NA I-12 D F NA NA I-13 D E NA NA I-14 B G A G I-15 A G NA NA I-16 D E NA NA I-17 D E NA NA -
TABLE 3 Covalent Modification Study: Inactivation Kinetics* kinact Ki kinact/Ki Compound # (min−1) (μM) (min−1M−1) I-1 0.3414 182.3 1872 I-2 0.6469 89.9 7801 I-5 0.9225 181.4 5085 I-8 0.0563 39.63 1420 I-9 0.368 165 2231 *hPAD4 isoform; Ca++ concentration = 10 mM
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/319,006 US10703741B2 (en) | 2016-07-27 | 2017-07-27 | Covalent inhibitors of PAD4 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662367389P | 2016-07-27 | 2016-07-27 | |
US16/319,006 US10703741B2 (en) | 2016-07-27 | 2017-07-27 | Covalent inhibitors of PAD4 |
PCT/US2017/044194 WO2018022897A1 (en) | 2016-07-27 | 2017-07-27 | Covalent inhibitors of pad4 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20190276432A1 true US20190276432A1 (en) | 2019-09-12 |
US10703741B2 US10703741B2 (en) | 2020-07-07 |
Family
ID=59523326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/319,006 Active US10703741B2 (en) | 2016-07-27 | 2017-07-27 | Covalent inhibitors of PAD4 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10703741B2 (en) |
EP (1) | EP3490989B1 (en) |
JP (1) | JP6987843B2 (en) |
KR (1) | KR102398941B1 (en) |
CN (1) | CN109790162B (en) |
ES (1) | ES2828623T3 (en) |
WO (1) | WO2018022897A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022232320A1 (en) * | 2021-04-27 | 2022-11-03 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
WO2023230609A1 (en) * | 2022-05-26 | 2023-11-30 | Celgene Corporation | Heterocyclic pad4 inhibitors |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201825476A (en) | 2016-02-23 | 2018-07-16 | 扣鎖醫療公司 | Heteroaryl inhibitors of pad4 |
ES2924522T3 (en) | 2016-09-12 | 2022-10-07 | Padlock Therapeutics Inc | Heteroaryl inhibitors of PAD4 |
PE20211067A1 (en) * | 2018-08-08 | 2021-06-09 | Bristol Myers Squibb Co | BENZIMIDAZOLES REPLACED AS PAD4 INHIBITORS |
KR20210042933A (en) * | 2018-08-08 | 2021-04-20 | 브리스톨-마이어스 스큅 컴퍼니 | Benzimidazole inhibitor of PAD enzyme |
KR20210042935A (en) | 2018-08-08 | 2021-04-20 | 브리스톨-마이어스 스큅 컴퍼니 | Substituted thienopyrrole as a PAD4 inhibitor |
SG11202101174RA (en) | 2018-08-08 | 2021-03-30 | Bristol Myers Squibb Co | Indole and azaindole inhibitors of pad enzymes |
WO2021084765A1 (en) * | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd | 4-aminobut-2-enamide derivatives and salts thereof |
MX2022006052A (en) * | 2019-11-22 | 2022-08-15 | Univ California | Caspase 6 inhibitors and uses thereof. |
EP4100405A1 (en) * | 2020-02-06 | 2022-12-14 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
MX2022013615A (en) * | 2020-04-30 | 2022-11-16 | Gilead Sciences Inc | Macrocyclic inhibitors of peptidylarginine deiminases. |
US11878965B2 (en) | 2020-12-22 | 2024-01-23 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1264037A2 (en) | 2000-02-09 | 2002-12-11 | Akzo Nobel N.V. | Pulping process |
CN1914168A (en) * | 2004-02-04 | 2007-02-14 | 公立大学法人横浜市立大学 | Peptidyl arginine deiminase type IV inhibitor |
WO2008000643A1 (en) * | 2006-06-29 | 2008-01-03 | F. Hoffmann-La Roche Ag | Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same |
EP2049536A2 (en) * | 2006-07-20 | 2009-04-22 | Genelabs Technologies, Inc. | Polycyclic viral inhibitors |
ES2609126T3 (en) * | 2012-07-26 | 2017-04-18 | Glaxo Group Limited | 2- (Azaindol-2-yl) benzimidazoles as PAD4 inhibitors |
WO2014149164A1 (en) * | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
EP3298003B1 (en) | 2015-05-21 | 2023-04-19 | GlaxoSmithKline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
AR107030A1 (en) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | AZA-BENCIMIDAZOL INHIBITORS OF PAD4 |
AR107032A1 (en) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | PAD4 BICYCLIC INHIBITORS |
TW201825476A (en) | 2016-02-23 | 2018-07-16 | 扣鎖醫療公司 | Heteroaryl inhibitors of pad4 |
ES2924522T3 (en) | 2016-09-12 | 2022-10-07 | Padlock Therapeutics Inc | Heteroaryl inhibitors of PAD4 |
-
2017
- 2017-07-27 EP EP17749074.5A patent/EP3490989B1/en active Active
- 2017-07-27 WO PCT/US2017/044194 patent/WO2018022897A1/en unknown
- 2017-07-27 KR KR1020197005300A patent/KR102398941B1/en active IP Right Grant
- 2017-07-27 CN CN201780059309.XA patent/CN109790162B/en active Active
- 2017-07-27 US US16/319,006 patent/US10703741B2/en active Active
- 2017-07-27 JP JP2019504110A patent/JP6987843B2/en active Active
- 2017-07-27 ES ES17749074T patent/ES2828623T3/en active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
WO2022232320A1 (en) * | 2021-04-27 | 2022-11-03 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
WO2023230609A1 (en) * | 2022-05-26 | 2023-11-30 | Celgene Corporation | Heterocyclic pad4 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
KR102398941B1 (en) | 2022-05-17 |
EP3490989A1 (en) | 2019-06-05 |
ES2828623T3 (en) | 2021-05-27 |
CN109790162B (en) | 2022-06-28 |
US10703741B2 (en) | 2020-07-07 |
JP6987843B2 (en) | 2022-01-05 |
JP2019525936A (en) | 2019-09-12 |
WO2018022897A1 (en) | 2018-02-01 |
EP3490989B1 (en) | 2020-09-09 |
CN109790162A (en) | 2019-05-21 |
KR20190035773A (en) | 2019-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10703741B2 (en) | Covalent inhibitors of PAD4 | |
US11897866B2 (en) | Heteroaryl inhibitors of PAD4 | |
KR102502992B1 (en) | Heteroaryl inhibitor of PAD4 | |
US9765093B2 (en) | Aza-benzimidazole inhibitors of PAD4 | |
US11981680B2 (en) | Substituted thienopyrroles as PAD4 inhibitors | |
US8729271B2 (en) | Glycine transporter inhibiting substances | |
JP7434281B2 (en) | Benzimidazole inhibitor of PAD enzyme | |
KR20210042934A (en) | Indole and azaindole inhibitors of PAD enzymes | |
US20220402950A1 (en) | Substituted benzimidazoles as pad4 inhibitors | |
US20230203039A1 (en) | Macrocyclic pad4 inhibitors useful as immunosuppressant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |